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ABSTRACT
Pulmonary drug delivery, as one of the most common alternative administration routes 
for injection, has been widely developed to perform effective local (e.g. asthma and 
chronic obstructive pulmonary disease) or systemic (proteins and peptides) therapy 
purpose. During this administration procedure, the therapy effects depend on many key 
factors, including fine powder properties, formulation of the drug powder, design of the 
dry powder inhaler, and operation of patients and so on. Especially, the mechanical 
structure of the dry powder inhaler plays the most important role, for example, the 
loading and emission consistency, air flow resistance, residue of fine drug powder, 
de-agglomeration construction, and the principle of generation of the powder aerosol and 
so on.
In this research, based on previous fundamental study on an old dry powder inhaler, a 
new dry powder inhaler has been developed and characterized. Different fine drug 
powder formulations were prepared to investigate the enhanced performance of the new 
dry powder inhaler. Several experiments, such as dose uniformity, emission consistency 
and in vitro particle deposition and distribution test, have been conducted to evaluate the 
new device. All the above test results were considered as the guide to modify and 
redesign the new dry powder inhaler. As an attempt, the puncture diameter of the new dry 
powder inhaler was increased, and the effects on the drug delivery performance were also 
evaluated.
In addition to the consideration of device design, studies on the formulation development 
have been carried out in this research. The effects of lactose with different particle size 
were compared as the carrier for the dry powder formulations. The drug formulations
were prepared by different methods, using coffee grinder or rotary blender, in order to 
optimize the production process. The effects of different amounts of carrier and stability 
test for the storage of formulation have been conducted.
This thesis successfully developed a new dry powder inhaler and discovered proper drug 
formulation for this device. With drug formulations using large lactose as carrier, the new 
DPI showed a good drug delivery performance with high consistency. Also a filling by 
hand process and a filling machine were developed and proved to be qualified for the 
application to dry powder inhaler.
Keywords: Dry powder inhaler (DPI), new generation, design and development, drug 
formulation, preparation and optimization, in vitro evaluation
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1.1 Introduction to Dry Powder Inhalers
Pulmonary drug delivery becomes more and more appealing treatment of respiratory 
diseases because of various advantages over the other administration routes, such as 
direct access to the targeting tissue with low side-effects, avoidance of first-pass 
metabolism for administration of many drugs, prevention of distinction of protein or 
peptides delivered by oral, and quick response with minimum dose amount and so on [1], 
To achieve effective drug delivery to the lung tissue, three types of device have been 
developed, including nebulizer, pressurized metered-dose inhalers (pMDIs) and dry 
powder inhalers (DPIs).
Compared with nebulizer and pMDIs, DPIs showed irreplaceable benefits in the 
pulmonary drug delivery, such as low side-effect (use of nebulizer could potentially 
cause the severe acute respiratory syndrome [2]) and avoidance of use of 
chlorofluorocarbon (CFC) (According to Montreal protocol 1987, CFC was called to 
phase out the production as propellant on 1 January 1996. [3]). Also DPIs showed a 
relatively simple structure, which could efficiently detach the drug particles from the 
carrier and deliver the particles into the deep lung tissue.
Several technical aspects should be considered carefully for the design and the 
development of DPIs. One of the aspects is the powder particle properties. According to 
the test requirements developed by the US Food and Drug Administration (FDA) and the 
European Inhalanda group [4, 5] for the approval of new DPIs, it was recognized that the 
particle size distribution and consistency of multiple dose are the most crucial 
characteristics of the DPIs. Meanwhile, other aspects for developing DPIs are also taken 
into account, such as drug product (device and all the parts, manufacturing, packaging 
and storage), drug formulation (component, composition, therapeutic effects, stability)
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and performance (dose consistency and accuracy, factors that affect flow rates and 
particle size distribution, and patient operation).
For commercialization of the newly designed DPI, the treatment method of drug powder 
formulations is a challenging issue during the development of DPIs. Because the dose 
amount of drug powder is quite low (usually around 1 mg) and the drug formulation is 
composed of fine dry powder (mean particle size 1-100 pm), the drug powder 
formulation usually showed a poor flowability, causing non-uniform dose so as to 
obstruct the filling process. Thus, it is important to develop suitable preparation methods 
and dose filling process for drug powder formulations.
1.2 Overview
This thesis contains two major parts. The first part was the characterizations of two DPIs, 
as well as the comparison of the drug delivery performance on different devices. The 
research works were listed as following:
•  To build old DPI and to investigate the drug delivery performance using in vitro 
evaluation tests with different drug formulations.
•  To design and produce new DPI and to evaluate the enhancement of drug delivery 
performance over the old one using in vitro evaluation tests.
•  To develop a simple hand-filling process on a lab scale for drug formulation applied 
into the two DPIs.
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The other part of the research work in this thesis was the additional modifications on the 
new DPI. Aspects on both device design and drug formulations were considered. 
Experiments of examination were listed below.
•  To modify the puncture diameter of the new DPI and to investigate the effects on 
the air flow resistance and drug delivery performance.
•  To change the particle size and the amount of carrier added into the formulation and 
to evaluate the effects on the formulation characteristics and drug delivery 
performance.
•  To develop a filling machine and a loading method for the blister of new DPI and to 
evaluate the dose uniformity, consistency and stability.
1.3 Thesis Structure
This thesis consists of seven chapters and follows the “Monograph” format outlined in 
the Thesis Regulation Guide by the School of Graduate and Postdoctoral Studies (SGPS) 
of the University of Western Ontario. It should be noted that the development of new DPI 
is still ongoing, especially for the modification of device and optimization of drug 
powder formulations. Therefore, chapter 6 only presented primarily results for work that 
remains in progress. The thesis structure is summarized below.
Chapter 1 presents a general introduction of pulmonary drug delivery and development 
of dry powder inhalers. Besides the project overview, thesis structure, as well as the 
major contributions of this research were included.
Chapter 2 reviews the literatures related to pulmonary drug delivery and dry powder 
inhalers. The development concerns of device and drug formulations for pulmonary drug 
delivery were also introduced in this chapter.
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Chapter 3 describes the development of two DPIs. Meanwhile, a simple hand-filling 
process and a filling machine are also developed in this chapter.
Chapter 4 evaluates the old DPI using formulation containing HNA and different lactose. 
Both formulation characterization and in vitro evaluation test were conducted to 
investigate the drug delivery performance.
Chapter 5 compares the drug delivery performance of new DPI. Enhancement on both 
drug formulation and drug delivery were proved over the old DPI.
Chapter 6 provides further research on new DPIs. Modifications on device and drug 
formulations were conducted and the effects on drug delivery performance were also 
evaluated in this chapter.
Chapter 7 summarizes the discoveries from the research study in this thesis and 
discusses the contributions and provide suggestions for future work.
1.4 Major Contributions
Four major contributions of this research were summarized as below:
•  Two DPIs were designed based on two different powder dispersion principles, 
using compressed air as driven powder vs. breath active. The design and structure 
of both devices were simple and practical. Considerable enhancements of drug 
delivery performance for new DPI were confirmed by in vitro evaluation tests.
•  The effects of lactose, including particle size and amount added into the formulation, 
on the powder characteristics and drug delivery performance were studied in this 
study. Large lactose was proved to be a better carrier for the drug formulations and 
no difference occurred when more lactose added into the formulations.
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A simple filling by hand process and a filling machine were developed for the 
loading, filling and sealing process of the blister. Both processes were investigated 
to be practical and qualified for the DPIs on a lab scale.
Additional modifications of both devices and drug formulations were conducted to 
optimize the drug delivery performance of new DPI. It was found that the increase 
in the puncture diameter could lead to an improvement of drug delivery 




2.1 Pulmonary Drug Delivery
Thousands of years ago, mankind had already been using the respiratory tract as a drug 
delivery route. In ancient Egypt, alkaloids smoke was generated by heating herbs for 
inhalation to treat cough and asthma [6]. Indian and Native American shamans also 
smoked or just burned the Datura stramonium leaves in a small room to apply the 
antiasthamtic therapy effects on patients [7], In the 19th century, the "fuming asthma 
remedies", asthma cigarettes, containing stramonium leaves, powders and cigars, were 
widely applied for the treatment of asthma [8]. During the last several decades, 
inhalation therapy has been considered as a valuable tool in the treatment of respiratory 
diseases, such as asthma or COPD (Chronic Obstructive Pulmonary Disease). Also 
some drug substances, including protein and peptide, which were required to obtain 
systemic absorption, had been proved to be administered successfully via respiratory 
tract delivery. Currently, more than 25 drug compounds have been commercialized as 
inhalation aerosol products for local pulmonary therapy effect and there were the equal 
amount of products in different stages of clinical development [9].
2.1.1 Lung Structure
All the above benefits of pulmonary drug delivery method are based on the unique 
structure of the lung, which plays the most important role in the respiratory tracts. 
Generally the lung is composed of two different functional zones: conducting airways 
(trachea, main bronchi and conducting bronchioles) and respiratory zone (respiratory 
bronchioles, alveolar ducts and alveoli), as indicated in Figure 2.1 [10]. And all these 
parts form a tree-like branching pattern, which is commonly subdivided into particular 
respiratory generations, starting with trachea (generation 0) while ending with the 
alveoli(generation 23) [11]. It is found that ciliated cells and goblet cells formed the
8
columnar epithelium of the upper airways. In the alveolar region, the monolayer 
epithelium is composed of type I and II cells, where all the air-blood transportation and 









Figure 2.1: Schematic overview of human airway structure. Schemes Andreas Henning 
modified after Weibel [12] and Forbes and Ehrhardt [13].
2.1.2 Advantages and Disadvantages of Pulmonary Drug Delivery
Recently, pulmonary drug delivery, as one of the most common medicine administration 
routes, has been attracting more and more interest from pharmaceutical and medical 
scientists, due to many advantages of inhalation therapy method, such as good patient's 
compliance, large surface area (~140 m2), rapid onset of action, reduced dosage to
9
produce pharmacological effect, less side-effects, and avoidance of first-past 
metabolism and so on.
However, pulmonary drug delivery is still have several disadvantages, for example, 
local side-effects due to oropharyngeal deposition, difficulty in correct operation by 
some patients, various factors affecting reproducibility of drug delivery to lung, short 
retention time of drug in the lung due to mucociliary clearance, and lack of practical 
pulmonary drug delivery device which could be easily used by patients [14].
2.1.3 Lung Deposition
In order to successfully deliver drug substance into lung tissue, an aerosol is the 
common medium, which could be generated by many different pulmonary drug delivery 
devices. Basically, the drug substance is dispensed in the therapeutic aerosol, which is a 
two phase colloidal system containing a liquid, solid or combination of the two as the 
dispersed phase. Therefore, the aerosol droplets or particles containing drug compound 
should deposit in the proper lung region with sufficient amount to achieve expected 
therapeutic effects.
Basically there are three principal deposition mechanisms for the pulmonary drug 
delivery process: inertial impaction, sedimentation and Brownian diffusion.
As shown in Figure 2.2, inertial impaction is the dominant mechanism for the particle 
(with particle size larger than 1 pm) deposition in the upper tracheobronchial regions. 
Because of the relatively larger momentum, these particles will maintain their original 
motion track when the inspired air flow changes its direction in the bifurcations, leading
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to collide on the airway walls. Consequently most particle with higher densities or 
larger diameters usually deposit near the bifurcations due to inertial impaction.
Air Flow
Figure 2.2: Different mechanisms of particle deposition at respiratory tract [14].
Sedimentation is a kind of particle deposition process due to gravity. More particles will 
settle in bronchioles and alveolar region, where the air flow becomes relatively low. The 
amount of particles deposited by the sedimentation mechanism relates to the time those 
particles spend during these regions.
For particles smaller than 1 pm, particle collisions take place on the airway walls 
because these particles could be displaced by gas molecules with random bombardment. 
The smaller the particles are, the more particles could be deposited by Brownian 
diffusion in regions with very low or even zero air flow, for example in the alveoli.
l i
2.1.4 Factors Affecting Particle Deposition in the Lung
A great number of factors, including physiological and pharmaceutical factors, may 
affect the aerosol deposition in the airways. Among the physiological aspects, the lung 
morphology, oral vs. nasal breathing, inspiratory flow rate, co-ordination of aerosol 
generation with inspiration, tidal volume, breath holding and some disease states play 
very important roles. So as to the pharmaceutical factors, the aerosol velocity, particle 
size, shape, density and physical stability should be taken into account.
Beside the above pharmaceutical factors, a new parameter, the aerosol dynamic particle 
diameter (D a ) has been introduced in order to describe the deposition behaviour of 
different types of aerosol particles. DA is the parameter of a unit density spherical 
particle (pP = 1 g»cm ') showing the same terminal settling velocity in still air. In terms 
of irregular particles, they can also be expressed by the equivalent volume diameter (D e ) 
and dynamic shape factor (y). De is the diameter of a spherical particle showing the 
same volume as the irregular ones, whereas the x is the ratio of the actual resistance 
force on a non-spherical particle to that on spherical one with the same volume and 
velocity. The DE could be calculated using the equation 2-1:
D a = D e x
\ X J
(2- 1)
Based on the above equation, most particles larger than 10pm will impact the upper 
airways, particles in the 3~5pm size range may settle in Tracheo-bronchial airways, and 
if the particle size is between 0.5~3pm they could deposit in the alveolar region, while 
submicron aerosol particles will not be deposited in the lungs because they could be 
removed by the exhaled airstream before sedimentation can occur [14].
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2.2 Development of Pulmonary Drug Delivery Devices
In order to deliver therapeutic aerosol to the lung tissue to achieve local or systemic 
effects, many technologies have been successfully developed during the past decades. 
The aerosol could be defined as a colloidal, relatively stable two-phase system, 
containing a gaseous continuum and highly dispersed condensed therapeutic matter. As 
we mentioned before, the dispersed phase may be solid, liquid or a combination of the 
two, which could be generated by certain device by an atomization process. The power 
required by the atomization process may be provided electrically, pneumatically or 
mechanically. Thus there are three principal types of aerosol generator applied in 
pulmonary drug delivery: nebulizer, pressurized metered-dose inhaler (pMDI) and dry 
powder inhaler (DPI). All these three different devices are designed based on different 
mechanisms in order to satisfy different therapeutic substances and patient groups. The 
development of modem pulmonary drug delivery devices could be described in Figure 
2.3. Table 2.1 summarizes the advantages and disadvantages of different devices used 
for aerosol generation.
2.2.1 Nebulizers
Nebulizers are pulmonary drug delivery devices, by which therapeutic drug solutions or 
suspensions can be converted into aerosol for inhalation. They are generally suitable for 
young patients, who cannot handle the other types of inhalers (DPI or pMDI) because of 
severe obstruction of the airway or insufficient coordination. Various drug substances, 
such as antibiotics, enzymes or mucolytic drugs, have been successfully applied in 
nebulizers due to lack of qualified formulations for DPI or pMDI. An atomization 
process occurs during the nebulizers converting liquid solution or suspension into
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aerosolized liquid particles, resulting in huge increase in the liquid-air interface and the 
transportation of droplets which requires large energy input. Therefore some forces are 
needed to govern this process, for example, surface tension, viscosity and aerodynamic 
forces. According to the different atomization mechanisms, there are two principal 




Hand Bulb Nebulizer 
( 1938)
Figure 2.3: Development of modern pulmonary drug delivery devices [15].
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Table 2.1: Advantages and disadvantages of different aerosol-Generators [16]
Type Advantages Disadvantages
Small-Volume Patient coordination not required Much less portable
Jet Nebulizer Effective with tidal breathing Pressurized gas source required
High dose possible Long treatment time
Dose modification possible Device cleaning required
Can be used with supplemental Not all medication available in solution
oxygen Does not aerosolize suspensions well
Can delivery combination Device preparation required
therapies if compatible Performance variable
Expensive when compressor added in
Poorest adherence
Pressurized Portable and compact Coordination of breathing and
Metered-Dose Treatment time is short actuation needed
Inhaler (pMDI) No drug preparation is required Device actuation required
No contamination of contents High pharyngeal deposition
Dose-dose reproducibility high Upper limit to unit dose content
Some can be used with Remaining doses difficult to determine
breath-actuated mouthpiece if no dose counter
Not all medications available
Valved Reduces need for patient More expensive than pMDI alone
Holding coordination Less portable than pMDI alone
Chamber Reduces pharyngeal deposition Integral actuator devices may alter 
aerosol properties, compared with 
native actuator
Dry Powder Breath-actuated Requires moderate to high inspiratory
Inhaler Less patient coordination flow
required Some units are single dose
Propellant not required Can result in higher pharyngeal
Small and portable deposition
Short treatment time Not all medications available (eg.




The basic principle for the generation of aerosol liquid particles by air-jet nebulizers is a 
two-fluid atomization process. Generally, a compressed air flow is introduced through a 
narrow hole and passed the port of one or more capillaries to entrain the drug solution 
by momentum transfer. Furthermore a liquid break-up process occurs, which is affected 
by the nozzle structure, turbulent rupture of the instable liquid column and secondary 
droplet break-up. According to different design of the nozzle, there are three types of 
air-jet nebulizers, such as conventional, open vent and breath assisted nebulizer.
As shown in Figure 2.4-a, Hudson T Updraft® nebulizer (Tefa, Nieuwegein, The 
Netherlands) is a conventional type air-jet nebulizers [17]. The pressurized air flow 
produced by the compressor (Devilbiss Pulmo-Aide) impinges on the entrained drug 
solution to generate droplets when it passes through the nozzle. Using a baffle, larger 
droplets are captured while the smaller ones are ready for inhalation by the inspiratory 
flow.
An open vent nebulizer, Sidestream® Medic-Aid (Romedic Meersen, The Netherlands) 
is as described as Figure 2.4-b. The auxiliary air flow introduced by the open vent also 
passes through the nebulization chamber, resulting in considerable enhancement of 
droplet entrainment from the nozzle area and a decrease in droplet concentration in this 
chamber. By this way, the coalescence of droplets and collision between the droplets 
and the inner wall of the nebulization chamber may be extremely reduced to obtain 
smaller droplet and higher drug output rate.
16
DeVibiss Pulmo-Aide




Figure 2.4: Schematic presentations of conventional air-jet nebulizers (a), open vent 
nebulizers (b) and breath assisted nebulizers (c). [17].
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Figure 2.4-c presents a breath assisted nebulizer, Ventstream, which contains a central 
air jet and four surrounding liquid capillaries. The entrainment occurs when the air flow 
impacts on a beam and skims the orifices of the capillaries. There is a flexible valve in 
the vent, which will open only during inhalation process; meanwhile, another valve will 
close the exhalation route, resulting in a higher nebulization performance and a lower 
waste of drug aerosol.
2.2.1.2 Ultrasonic Nebulizers
Figure 2.5 indicates the generation mechanism of drug aerosol by an ultrasonic 
nebulizer. A piezoelectric element is placed in the drug solution, and vibrates at high 
frequency ultrasound waves to cause atomization of drug liquid around a feeding tube, 
and to turn it into a peristaltic pump, which pushes the liquid through a ceramic mesh to 
form aerosol cloud. Then the therapeutic aerosol drug droplets are carried by the 
inspiratory flow to the air way. Compared with the jet nebulizers, current ultrasonic 
nebulisers could not nebulise drug suspension efficiently.
Air
Figure 2.5: Schematic diagram of an ultrasonic nebulizer [18].
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2.2.2 Pressurized Metered-dose Inhalers (pMDI)
Because of some disadvantages of nebulisers, such as fragile design, varied dosage 
amount, and poor consistent drug delivery, in the middle 1950s, some kind of 
pressurized containers were developed by Riker Laboratories (now 3M Pharmaceutics) 
to deliver bronchodilator drug formulations, which showed greater convenience and 
more reliable dosage [19]. Pressurized metered-dose inhaler, shown in Figure 2.6, turns 
to be the most important device for the delivery of inhaled therapeutic drugs. In the 
early 2000s, approximately 500 million dollars were generated from these products 
annually [21]. The pMDI, once termed "the most complex dosage form used in 
medicine today" [22], is generally composed of a container, propellants, drug, a 
metering valve and an actuator.
2.2.2.1 Container
The container, or canister, which is used to hold the propellant and drug formulation 
should meet the following requirements: a) the container must be made of inert and 
health safe material, which could not interact adversely with the propellant; b) the 
container must be able to withstand the high pressure produced by the propellant at the 
normal operation conditions by the patients; and c) the material used for the container 
must be compactable. A CocaCola bottle was used as the container in the first prototype 
pMDI and smaller (10 mL) glass bottles were also used in the earliest marketed 
pMDIsw [19]. However, the most current marketed pMDIs have containers made by 
aluminum, because this material, compared to glass or even stainless steel, is much 
lighter, more compact, less fragile, and opaque. Sometimes, some coatings are applied 
in the internal container surface to avoid adhesion of drug particle and degradation of 
therapeutic component [23].
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Figure 2.6: Schematic diagram of typical pressurized metered-dose inhaler [20]. 
2.2.2.2 Propellants
Some special gases are in gaseous phase at atmospheric pressure but could be liquefied 
by compression. They could be used in pMDIs as propellants because they are nontoxic, 
nonflammable, and compatible with solutions or suspensions of drug formulations, and 
have suitable boiling point and densities [24], Chlorofluorocarbons (CFCs) are the 
traditional propellants used in pMDIs, which contain volatile Dichlorodifluoromethane 
(CFC-12) as the major component. Trichlorofluoromethane (CFC-11) and 
Dichlorotetrafluoroethane (CFC-114) have been used to adjust the vapour pressure 
during the preparation of the formulation due to their higher boiling points. In order to
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provide a constant vapour pressure (usually 300-500 kPa) in spite of whether the 
container is full or nearly empty, CFCs could form a 2-phase (saturated vapour and 
liquid) equilibrium within the closed container.
But currently, CFCs cannot be used any more as propellants due to the release of 
chlorine during degradation, which could destroy the ozone layer in the stratosphere
[25] . The 2 hydrofluoroalkanes (tetrafluoroethane [HFA-134-a]) and 
heptafluoropropane (FIFA-227) turned to be the alternative propellants in the market
[26] . But HFAs are not same as CFCs, even though they have similar thermodynamic 
properties. So that problems occurred with the reformulation of FIFA propellants in 
pMDIs, such as some new type of excipients and metering valves are required to meet 
the new formulations [27, 28]. Novel filling method is also needed for HFA products 
[29], toxicity and clinical testings are also necessary to be undertaken.
2.2.2.3 Drug Formulation
Table 2.2 lists some formulations used in marketed pMDIS [30], Drug is generally 
prepared into formulation either as a solution, or as a suspension of micronized particles. 
In term of suspension formulation of CFCs, some kinds of surfactants (oleic acid, 
sorbitan trioleate or lecithin) are usually used to prevent the particle aggregation and to 
lubricate the valve. In case of solution CFCs formulations, a co-solvent is probably 
required, such as ethanol, antioxidants and flavouring agents [31]. As mentioned in 
description of propellants, some alternative formulations based on HFA have been 
developed by some companies to replace the CFC pMDIs [32], and these newly 
designed inhalers showed better lung deposition [33] and clinical efficiency in smaller
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dose [34]. The suspension-formulation pMDIs must be immediately shaken before use 
to make sure that the drug particles could disperse uniformly in the propellant and 
therefore obtain a reproducible dose [35]. The current marketed pMDIs could only 
deliver 100-200pg of drug per shot due to the valve clogging limit [36], while some 
solution-formulation pMDIs may give 1.0-1.5 mg of fine drug particle per shot [37].
2.2.2.4 Metering Valve
The metering valve was originally designed for the cosmetic products, which facilitated 
the initial conception of potential method for pulmonary drug delivery. Based on the 
patent of a metered valve by Emson Research and pressure-resistant vials by Wheaton 
Glass Company, the first pMDI was developed by Riker Laboratories in 1955, and 
simple exposure research and clinical trials were carried out in the following year, 
leading to the approval of Medihaler ® in March, 1956. As described in Figure 2.7, 
most metered valve work with the basic principle [38], Generally, before the pMDI is 
fired (the valve stem (B) is pressed), there will be a channel linking the reservoir (A) 
within the canister (C) and metering chamber (E), resulting in the filling of liquid 
propellant to the chamber. Then the metering chamber is connected to the atomisation 
orifice to release the liquid through the valve exit (F) when the valve stem is depressed, 
while the channel to the canister is closed.
Beside the basic principle indicated by Figure 2.7, some alternative designs have been 
developed, such as plug type metering valves, chamberless valves, capillary ports filling 
valves and groove filling valves. Compared to the household aerosol products, all the 
valves used in pMDIs are in the inverted position without dip-tube applied.
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Table 2 .2 :  D ru g  fo r m u la t io n s  u s e d  in  m a rk e te d  p M D Is  [30 ]
Product Company Drug Formulation Propellants
Ventolin® GlaxoSmithKline Salbutamol Suspension CFC 11/12
Becotide® GlaxoSmithKline Beclometasonedipropionate Suspension CFC 11/12
Flixotide® GlaxoSmithKline Fluticasonepropionate Suspension CFC 11/12
Maxair™ 3M Pharmaceuticals Pirbuterol Suspension CFC 11/12
Proventil® Schering - Plough Salbutamol Suspension CFC 11/12
Berotec® BoehringerIngelheim Fenoterol Suspension CFC 11/12/114
Ventolin






Proventil® via agreement with Salbutamol Suspension HFA-134a
3M
Airomir® Ivax, via agreement with 3M Salbutamol Suspension HFA-134a
QVAR® Ivax, via agreement with 3M
Beclometasone
dipropionate Suspension HFA-134a
Alvesco® Altana Ciclesonide Solution HFA-134a
Intal® Sanofi-aventis Sodiumcromoglicate Suspension H FA-227






Figure 2.7: Schematic diagram of the mechanism used in metered valves [38].
2.2.2.5 Actuators
Actuator is one of the most important multifunctional components in the pMDI, which 
connects the atomisation orifice (with a mouthpiece adaptor) and a valve stem 
(combining the valve and pressurised canister). The design of the actuators, especially 
the diameter of the nozzle, is very important, because the particle size of the aerosol 
generated by the actuator is dependent on the nozzle diameter (0.14-0.6mm), 
consequently leading to influences on the lung deposition of aerosol [39]. The final 
aerosol is generated by a atomization process, i.e., a 2 phase gas/liquid air-blast [40], 
Briefly, the aerodynamic forces generated during the dose passing through the actuator 
nozzle could pull apart the liquid ligaments embedded in the propellant vapor, result in 
a uniform dispersion of liquid droplets. And those droplets will be cooled down because 
of the evaporation of propellant during the atomization process, but the decrease of 
temperature will be less for the HFA formulations [41].
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2.2.3 Development of Dry Powder Inhalers (DPIs)
Dry powder inhalers (DPIs) are medical devices by which dry powder formulations 
containing therapeutic component could be effectively pulmonary delivered to treat 
local or systemic disease. Comparing with nebulizers and pMDIs, DPIs have been the 
most rapidly expanding pulmonary drug delivery devices because of many advantages, 
such as direct deposition of drug powder into the deep lung, avoidance of using 
propellant gases, no need for coordination of inhalation and actuation, are portable, 
patient friendly and easy to use and so on.
In 1969, the first modem DPI occurred with the introduction of Spinhaler (Aventis) 
'unit-dose' DPI, in which sodium cromoglycate was applied as therapeutic drug. And in 
the mid 1970s, Rotahaler 'unit-dose' DPI was developed by GlaxoSmithKline to 
delivery sulbutamol to treat asthma [42], However these DPIs used individual capsules 
to contain the drug powder which leads to relative inconvenient. Therefore more 
patient-friendly devices containing multiple dosed in blisters, individual capsules or 
even in a bulk powder reservoir came into market in the late 1980s. For example, 
GlaxoSmithKline developed the first multi-blister used DPI, Diskhaler, followed by 
Diskus, the product of Accuhaler in UK, and AstraZeneca introduced the earliest 
reservoir device as Turbuhaler.
2.2.3.1 Current DPIs on the Market
During the development of DPI products, the design of inhaler device is critical and 
most important. Currently, more than 20 DPI devices could be found on the market and 
still over 25 are in development. Some successful DPI products which are applied in 
clinical are selected as described as Figure 2.8 [43].
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Figure 2.8: Photographs of some currently marketed DPI devices. (A) Aerolizer™, (B) 
Easyhaler™, (C) Turbohaler™, (D) Diskhaler™, (E) Novolizer™, (F) Rotahaler™, (G) 
Clickhaler™, (H) MAGhaler™, (I) Spinhaler™, and (J) Handihaler™ [43].
According to the delivery mechanism, current available DPIs could be divided into three 
main categories, i.e., the first generation DPIs, the second generation DPIs and the third 
generation DPIs, as listed in Table 2.3. Some single unit-dose breath activated inhalers 
are considered as the first generation DPIs, such as the Spinhaler ® and Rotahaler®. 
With these DPIs, drug -carrier agglomerates or mixtures were delivered by patient's 
inspiratory flow and the drug delivery performance will depend on the particle size and 
deagglomeration. A better technology, multi-dose DPI or multi unit-dose DPI was 
applied in the second generation DPIs, in which sufficient turbulence and
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Table 2 .3 :  C u r r e n t  m a rk e te d  D P Is .
Device DPI type Company Deliverymethod
Drug and 
diseases
First generation: breath actuated single unit dose
Spinhaler Single dose Aventis Capsule SC, Asthma
Rotahaler Single dose GlaxoSmithKline Capsule SS, Asthma
Inhalator Single dose Boehringer-lngehrim Capsule Fenoterol, Asthma
Cyclohaler Single dose Pharmachemie Capsule SS, Asthma
Handihaler Single dose Boehringer-lngehrim Capsule Tiotropium, COPD
Second generation: breath actuated multi-unit, multiple dose
Turbohaler Multi-dose Astra Zeneca Reservoir SS, Asthma
Diskhaler Multi-unit dose GlaxoSmithKline Blisterpackage SX, Asthma
Diskus Multi-unit dose GlaxoSmithKline Strip pack IB, Asthma
Aerohaler Multi-unit dose Boehringer-lngehrim -
Easyhaler Multiple dose Orion Pharma Reservoir SS, Asthma
Ultrahaler Multiple dose Aventis Reservoir SS, Asthma
Third generation: active device
Exubera Single dose Pfizer Blister Insulin, Diabetic
Aimax Multi-dose Norton Healthcare Reservoir Formoterol, Asthma
particle-particle collisions were provided to detach the drug particles from the carrier 
surface or to deagglomerate drug particles from large agglomerates of drugs. A 
fluidization of drug particles could be performed with tangential air flow during the 
patient inspiration by various mechanisms, for example by pressing (Rotahaler®), 
rotating (Twisthaler®), piercing (Handihaler®) or sliding (Spinhaler®). The active 
devices are as known as the third generation DPIs, in which compressed gas, motor 
driven impellers or electronic vibration were applied to disperse drug particles from the
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formulations. Because an energy source is applied to enable the delivery of drug, the 
third generation DPIs showed better reproducibility and dose accuracy.
2.2.3.2 Different Designs of DPIs
Generally, a basic DPI consists four main parts: dose (measuring) system, powder 
formulation, powder de-agglomeration principle and mouthpiece, as described in Figure 
2.9 [44]. An air stream is introduced into the DPI through the air inlet, passes the dose 
metering system to entrain the drug powder, then generates the aerosol particle by the 
powder de-agglomeration principle, followed by inhalation through the mouthpiece to 
enable the pulmonary drug delivery. Some kinds of secondary inhaler parts may be 
added onto the primary DPI in order to fulfil various functions, such as good safety 
performance, easy operation, excellent patient compliance or moisture protection.
The metering system, which is considered as the most critical part in DPIs, may be a 
capsule or blister with pre-weighted unit doses of drug powder formulation. There are 
some different piercing or opening mechanisms applied to realize the access of the 
powder formulation, but the discharge of capsules or blisters and dispersion of powder 
into the air stream take place at the same time in the most DPIs. In some newly 
developed DPIs, such as Eclipse ™ (Aventis) and Spiros (Dura Pharmaceuticals), 
additional powder de-agglomeration mechanisms have been applied to enhance the fine 
powder fraction (FPF) [45],
Based on the single dose DPIs, an alternative design, multi-dose reservoir system has 
been developed recently and applied into DPIs. As shown as Figure 2.10, some disks 
with well-defined orifices (Turbuhaler®, Astra-Zeneca) or slides with accurately 






Figure 2.9: Basic functional design elements of DPI [44],
Powder reservoir
Turbuhaler® Novolizer® Ratiopharm® Jethaler
Figure 2.10: Different multi-dose reservoir and metering mechanisms used in DPI [44].
Dose measuring cavity Ring tablet Scraper disk
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each dose of drug powder formulations. But these DPIs must be kept in an upright 
position during the inhalation operation, because the powder metering compartments 
were filled from powder bulk reservoirs due to gravity. Thus very good flowability and 
homogeneity of the powder formulation are usually required to ensure uniform filling.
Also some other concepts have been introduced into the dose metering system, an 
example is Jethaler® (Rationpharm), a scraper disk was designed to grate certain 
amount of powder from a ring compact of the drug-excipient mixture during the 
inhalation operation. This design could also be seen in Ultrahaler (Aventis), which 
unfortunately showed quite poor dose reproducibility [46].
2.2.3.3 Principle of DPIs Design
Particles of excipient with larger size than micronized drug powder, usually lactose or 
mannitol, are generally applied in most DPIs as carriers, in order to prevent the 
aggregation and to enhance the flowability. As indicates in Figure 2.11, drug powder is 
blended with carrier particles and loaded into powder reservoirs, for example, simple 
reservoir, blister disk, blister strip or capsules, then moved through dispersion design to 
generate aerosol cloud, which is finally inhaled into the patient's airway leading to 
therapeutic effects. In most DPIs, force of shear or turbulence created by the patient's air 
flow is the main driven source for the movement of drug-carriers mixture from the static 
powder bed. The better fluidized effects are obtained, the higher delivery efficiency 
could be achieved. While the drug-carrier aerosol enters the patient's airway during the 
inhalation, the drug particles will separate from the carrier particles and be carried into 
deep lung by the air flow, while the carrier particles impact in the oropharynx and then 
are cleared by the body.
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Formulation Metering Dispersion Oropharyngeal Deposition Pulmonary Delivery
Passive,'Active
Figure 2.11: Principle of DPI design [47].
Different dispersion mechanisms have been applied in the DPIs, including both passive 
and active DPIs. As mentioned above, most DPIs are passive ones, which are activated 
by patient's breath, while some other active devices have been developed recently, such 
as pneumatic, impact force, and vibratory power-assisted DPIs. Due to the breath 
independent dispersion mechanism, these devices showed higher delivery efficiency 
and reproducibility, which are suggested to deliver systemically active drug with narrow 
therapeutic windows [48].
2.2.3.4 Formulations for DPIs
Besides the mechanical design strategy of DPIs, the formulation of drug powder applied 
in DPIs is another important factor, which affects the performance of inhaler device, 
such as the generation, delivery, and deposition of aerosol cloud. In order to ensure the 
delivery of drug to the lungs, followed by effective absorption, drug particles have to be 
brought out of the device and of course to be separated from the carrier particles and
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from each other. Therefore the drug formulation applied to DPIs is required to undergo 
flow, fluidization and de-aggregation. However the drug particles, which were produced 
usually by high-energy operations (jet milling, ball milling), always show a poor 
flowability because of high surface areas and surface energies. The attempts of 
formulation research are supposed to solve those problems. Taking the formulation 
factors into account, several aspects are generally focused on by pharmaceutical 
researchers, for example, the characteristics of drug formulation (especially powder 
flowability, particle size, shape and surface properties) and drug carrier interaction [49].
One way to enhance the flow property of powder formulation in DPIs is to add larger 
excipient particles as carriers. Excipients applied in DPIs are required to be "generally 
recognized as safe" substances. These materials should be inactive ingredients and not 
intended to exert the therapeutic effects of drugs, but they are expected to enhance the 
physical and/or chemical properties of drug compounds, for example, to get a better 
flowability, dispersion behaviour, and deep lung deposition. Unfortunately, limited 
amount of excipients have been accepted and approved by the Food and Drug 
Administration (FDA) for application in respiratory drug delivery. So as to DPIs 
formulations, the excipients are expected to be biocompatible, endogenous to the lung, 
and easily metabolized or cleared. The excipients usually applied in DPIs include the 
following compounds: sugars (lactose, glucose, mannitol and trehalose), hydrophobic 
additives (Mg stearate), lipid (cholesterol, dipalmitoyphosphatidylcholine et al), amino 
acid (leucine and trileucine), surfactants (poloxnmer and bile salts), absorption 
enhancers (hydroxypropylated- P -cyclodextrin, chitosan and bile salts), and 
biodegradable polymers (copoly lactic acid/glycolic acid) [50],
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Since the unit dose of DPIs is only around a few milligrams, a larger amount of 
excipients are added into the formulation to provide bulk, in order to make it easy for 
handling, dispensing and metering. Usually, to prepare the drug formulations for DPIs, 
both drug ingredients and excipients are required to treated by particulate process and 
equipment, resulting in better performance, such as narrow particle size distribution, 
improved flowability, enhanced dispersibility, increased drug stability, optimized fine 
particle deposition in lung, finally better therapeutic effects with less side effect. 
Furthermore, several techniques have been developed to produce dry powder 




CHARACTERIZATIONS OF NEW DRY POWDER 
INHALER (DPI) AND FILLING MACHINE
34
3.1 Introduction
DPI, as the most acceptable device in current clinical treatment, should be designed to 
provide a condition in which the drug ingredients keep their physicochemical stability 
and generate reproducible dose of therapeutic aerosol, therefore leading to a higher fine 
particle fraction (FPF) of drug powder deposition in the deep lung. In order to achieve 
good device reliability, therapeutic effects and patient compliance, an ideal DPI should 
have the following important characteristics [51]:
1) the device should be easy to operate, convenient to carry, and keep the drug 
formulation stable in environment[52];
2) the device should deliver accurate multiple doses of aerosol with uniformity, and an 
audiovisual part should be designed to indicate the consumption of doses [53];
3) the delivery of dose should be consistent throughout the life of the device [54];
4) a good dispersion of drug powder and qualified fine powder deposition in deep lung 
should be achieved [55];
5) applications to a wide range of drug formulations [56];
6) low cost with good drug delivery efficiency [57] and
7) suitable design and easy operation for patients to refill drug reservoir [58],
Therefore a successful or promising DPI should be designed following the above 
guideline. In recent decades, a large amount of DPIs with different designs and various 
types of drug dispersion mechanisms have been developed. But most of these products 
showed both considerable advantages and disadvantages, and none of them could provide 
a superficial efficiency in drug delivery into deep lung. Worldwide pharmaceutical 
researchers have spend more and more efforts in developing novel DPI combined with 
specific drug powder formulations.
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Besides the three main categories of DPIs mentioned in chapter 2, the recently developed 
DPIs could also be divided into two majority types, passive DPI and active DPI. The 
passive DPIs are designed to deliver the drug powder by the air flow generated by the 
patient's breath, in which the drug delivery efficiency seems to be affected by the air flow 
and the operation of the patients. But these kinds of DPIs show a great advantages, for 
example, easy to use, compact size and lower cost. On the other hand, the active DPIs are 
usually driven by extra power, including electric power, ultrasonic or compressed air. 
These types of DPIs theoretically provided uniform dosage, but always come with a 
larger size, more complicated structure and higher cost.
Based on many years of research on pulmonary drug delivery, various DPIs have been 
developed by our research group, which indicated the growth of fundamental research 
and commercialization development of DPI in our pharmaceutical research group. In this 
research paper, the latest two types of DPIs were studied and different dry powder 
formulations were applied to evaluate their drug delivery efficiencies.
3.2 Old DPI
The old DPI is an active DPI, which is associated by the compressed air generated by a 
small cylinder. As indicated in Fig 3.1 a, the old DPI is composed of four parts: cover, 
mouth piece, main body and the blister. When the DPI is not in used, the whole mouth 
piece will be completely covered by a full cover, which provides protection for the 
portable mouth piece.
Fig 3.1 b shows a detailed structure of the mouth piece. The mouth piece (Part 1) is 
designed into a three layer cap, which could be fixed onto the main body by an L shape
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Figure 3.1: The diagram of old DPI and blister.
fastener (Part 2). The first layer is used as the portable part (Part 3) connecting the 
patient's mouth, where the aerosol cloud containing drug and excipient powder are 
carried out by the air flow. The second layer (Part 4) with screw thread, as the controlling
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switch, could be shifted by finger for the dosage change. Also there is a small window 
(Part 5) that displays the dose number on the blister, which is to inform the patient about 
how many doses have been used, thus remind the operator when to reload the blister.
Figure 3.1 c and d show the inside structure of the main body of the old DPI. The main 
body (Part 6) provides the required space for the cylinder (Part 7) to generate compressed 
air, resulting in air flow which passes through the blister (Part 8). The blister containing 
drug powder formulation is placed on the top of the main body and located by the mouth 
piece, in order to make sure that the dose dot could connect with the channel (Part 9) 
within the mouth piece. Thus, when the compressed air is released from the cylinder, and 
passes through the blister, it will bring the drug powder into the channel and exit from the 
mouth piece, where performs an aerosol cloud. When this administration is completed, 
the blister could be moved clockwise by the dose changing switcher (Part 4), the number 
in the dose counting window will change to number 2, and then the next inhalation 
operation is ready.
The blister design shown in Figure 3.1 e and f, contains two separated parts, plate (Part 
11) with dose holes (Part 14) and support column (Part 13). A paper filter (Part 12) is 
placed between the plate and column in order to keep the powder during the filling 
process. On the plate (019.05 mm) there are 16 dose holes with accurate diameter 
(01.016 mm) and depth (1.016 mm), which are used to measure each dose (according to 
Equation 3.1).
In the laboratory, this blister was filled manually, which process was described in Figure 
3.2. Briefly, the blister was placed into a holder (Part 10) which is connected to a certain 
vacuum time (Part 16). The drug powder formulation (Part 15) was piled on the plate,
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then open the connection to vacuum and scratch the powder pile over each dose holes 
three times, in order to make sure that the powder could fill all the holes completely and 
uniformly. After that, release the vacuum; get rid of the extra powder on the plate, then 
take the filled blister off the holder.
15 14
16
Figure 3.2: The diagram of filling process of blister.
3.3 New DPI
Based on the old DPI, a new DPI has been developed by our research group, as shown in 
Figure 3.3. This newly designed DPI exhibited a simple structure and compact size, 
which could be easily handled, including operation, storage, dose counting and reloading 
the blisters.
The new DPI is composed of two main parts, the cover (Part 1) and main body (Part 2). 
The cover is designed into two separated parts, one for the cover and release of the mouth 
piece (Part 3) and the other part for the opening of the main body to reload the blister. 
The tortoise-like main body contains mouth piece, puncher (Part 4), press-button (Part 5), 
dose counting window (Part 6) and dose changing switcher (Part 7).
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c d
Figure 3.3: The diagram of new DPI.
The puncher (Part 4) is the critical part of the new DPI, which contains several special 
designs (Figure 3.3 b). Within this small puncher, there is an L-shape tube with two exits, 
one regular exit (Part 8) and one with a sharp end (Part 9). Specially, four small grooves 
are designed on the body close to the sharp end, which allow extra air flow goes into the 
dose hole to carry out the powder during the inhalation process.
Figure 3.3 c and d indicate the loading of blister (Part 11) and the operation of inhalation 
with this DPI. Briefly, open the main body, install a well full filled and sealed blister into
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the holder of the main body, close the main body and adjust the blister position by the 
dose changing switcher (Part 7) until the dose counting window shows the number 1. 
Then it is ready to deliver the formulation to the patient.
When we press down the press-button (Part 5), the puncher (Part 4) will be driven 
downward, the exit 8 will get into connection with the mouth piece (Part 3), meanwhile, 
the sharp end down to break the sealing film on the dose dot, and the drug powder will be 
carried out by the air flow when the patient take a deep breath through the mouth piece. 
As long as this administration is finished, the blister could be moved clock wise by the 
dose changing switcher (Part 7), the number in the dose counting window will change to 
number 2, when the next inhalation operation is ready.
3.4 Preparation of Blister for New DPI
Since this research is still in the laboratory stage, the blisters were prepared by 
homemade equipment. The blister was made by polyvinyl chloride (PVC) material, 
which is widely used for the packaging of pharmaceutical products. As described in 
Figure 3.4, firstly, the PVC plate (Part 1) was placed on the blister holder with regular 
cavities (Part 2). Then the plate was heated by heating source (Part 4), at the same time 
the vacuum (Part 3) was applied into the holder. The polymer was melted and sunk into 
the cavities due to vacuum. When all the cavities were covered by the melted polymer, 
rthe heating source was removed and cooled down the plate by cold compressed air, then 
the blister (Part 5) was obtained. During this process, the heating time and temperature, 






Figure 3.4: Diagram illustrating preparation of blister for new DPI.
3.5 Filling Machine for New DPI
A very valuable attempt for the development of new DPI is the design of a filling 
machine for the full filling of blister in laboratory, which could be a very important guide 
line for the scale-up manufacturing in the pharmaceutical industry.
The filling unit of the filling machine is as described in Figure 3.5 a. This operation unit 
contains feeding chamber (Part 1), dosing plate (Part 2), vacuum system (Part 3) and 
loading system (Part 4). And Figure 3.5 b and c illustrated the structure of the filling unit 
as well as the filling process. When the filling unit was set up at position 1, drug powder 
formulation was added into the feeding chamber (Part 1) and piled over the dose cavities 
(Part 2) of the dosing plate. Then vacuum (Part 3) was applied into the system, and this 
whole unit was rotated clockwise for three cycles. When it reaches the initial position, the 
drug powder could fill up all the dose cavities because a filter (Part 5) made by porous 
material could keep all the powder from the vacuum. Then the vacuum was released, and 
the dosing plate was slided to position 2, as showed in Figure 3.5 c. The extra powder
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over the plate was scratched off by the feeding chamber, because of a sharp edge that was 
designed at the bottom. With a vibration applied on the dosing plate (Part 8), the drug 
powder formulation contained in the dose cavities will drop into the blister (Part 7), 
which was settled on the blister holder (Part 4). Then the dosing plate was slided back 












Figure 3.5: Diagram illustrating the filling machine for blister of new DPI, (a) filling 
machine and the parts; (b) position 1 for filling process; and (c) position 2 for filling
process.
The fully filled blister was then placed on the holder, and sealed by Laminated films and 
pouches (PET/AL/PE) material using a flat iron. This sealing process is quite similar to 
the steam pressuring of clothes with the iron. Then the well sealed blister was cut and 
ready to load into the DPI.
3.6 Conclusions
In this research, two types of DPIs were developed to deliver dry drug formulation into 
deep lung. The old DPI, as an active DPI, could be applied to formulations with very 
small dosage amount, due to the small volume of dose cavities on the dosing plate. 
Compressed air generated by the cylinder could pass through the dose cavities on the 
blister to carry out the powder, and produce aerosol cloud after exiting from the mouth 
piece. 16 doses are contained on each blister, which could last for more than 2 weeks' 
treatments of usual COPD. Each dose was accurately metered by the dosing plate.
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This study also designed a new DPI, based on the research of the old one. As a passive 
DPI, the new DPI showed many advantages over the old one, including more simple 
structure, lower cost, larger dose amount, easier operation and so on. The most exciting 
development is that the blister could be well sealed and will show very good stability 
during storage condition, as well as convenience for reloading of blisters. Also, a filling 
machine was developed to test and verify the possible application of this filling method in 
industrial manufacturing process.
Moreover, the filling process and reloading operation are very simple, and could bring
many benefits to the patient.
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CHAPTER 4
EVALUATION OF OLD DRY POWDER INHALER
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4.1 Introduction
Due to the perceived limitations of pressurised metered dose inhalers (pMDIs) and 
nebulisers [59], DPIs have been representing the most dramatically expanding field in 
pulmonary drug delivery in recent decades. Compared with pMDIs and nebulisers, DPI 
showed exciting advantages, including avoidance of use of propellant gases, no need of 
coordination and actuation, no need for spacers, being portable, operation friendliness, 
and easy to use [60]. Since DPI plays the most important role in obtaining efficient 
delivery of drug formulation into deep lung tissue, the device should be designed and 
developed according to the ideal DPI characteristics, as mentioned in Chapter 3. While 
no DPI could achieve all those ideal conditions; considerable attempts should be made to 
enhance their drug delivery performance where necessary. Thus, during the development 
of DPI, the evaluation of the DPI performance is even more important than the design 
and manufacturing, which could provide feedback invaluable ideas and to drive the 
modification and development of the inhalation device.
Usually, the efficiency of delivering drug powder formulation into deep lung tissue 
depends on several interrelated factors, for example, the design of inhaler device 
including mechanism of aerosol generation and drug powder dispersion, proper 
inhalation technique leading to efficient lung deposition, properties of drug powder 
formulation including powder flowability, particle size and distribution and drug-carrier 
separation principle [61-63]. Thus the actual inhaler device is always evaluated alongside 
the drug formulation for DPI.
In this research, to evaluate the drug delivery effects of DPI, several factors related to the 
device are generally taken into account by in vitro evaluations, including dose uniformity 
test, emittion test, and in vitro lung deposition test. In regards to the drug powder
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4.2 Experimental Methods
In this study, both lactose powders with two different particle sizes were used as the 
carrier for the pulmonary drug delivery. With l-Hydroxy-2-Naphthoic acid (HNA) as the 
model drug, two formulations (formulation 1 is the mixture of HNA and fine lactose, and 
formulation 2 is the mixture of HNA with large lactose) were prepared to evaluate the 
delivery efficiency of the old DPI.
To prepare the formulation of HNA and lactose, formulated amount of HNA and lactose 
(at ratio of 1:4) were put into a coffee grinder. The mixture was ground 5 times, for 5 
seconds each time, enough long intervals were provided to make sure that the 
temperature of the mixture would not rise too high during the grinding process.
4.2.1 Particle Size and Distribution
Considering the powder characteristics of the drug formulation, many aspects affect the 
delivery efficiency of DPI, such as particle shape, density, electrical charge and 
hygroscopicity. Besides those issues, the particle size and distribution is one of the most 
important design variables during the development of drug formulation, because the 
distribution and deposition of particle in the respiratory tract depend on the particle size 
delivered by the DPI. Basically, the three principle mechanisms (impaction, gravitational 
sedimentation and diffusion), which decided the fate of the inhaled particles, could occur 
on particles with different ranges of sizes. The particles larger than 5 pm normally 
deposit on the surface of conducting airways by the impaction, gravitational
formulation, several characteristics are measured to evaluate the powder properties, such
as particle size and distribution, angle of repose, and particle surface morphology.
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sedimentation helps the particles over 0.5 pm and below 5 pm to be settled in small 
conducting airways, and the particles smaller than 0.5 pm usually show a random motion 
in small airways and alveoli by diffusion. Therefore, the particle size of ideal drug 
formulation should be controlled between 0.5 pm and 5 pm, especially with a narrow size 
distribution. But unfortunately, no powder formulation could reach the above 
requirements, and what we can do is to try to find a balance between the particle size and 
delivery efficiency, which could guide our development of DPI.
In this experiment, pure HNA, fine lactose, large lactose and two formulations composed 
of HNA and different lactose were tested by Particle Size Distribution Analyzer (PSDA, 
TSI ® Model 3603), the particle size and distribution were obtained. Each sample was 
measured three times for statistical accuracy.
4.2.2 Angle of Repose
Besides the particle size and distribution, the flowability of powder formulation is also an 
important aspect, which could affect the dose uniformity, dose filling consistency, and 
even dispersion of drug particles from the carriers. To evaluate the flowability of drug 
formulation, many instruments are widely used in powder technology research, including 
rotational bed expansion ratio (RBER), avalanche angle (AVA) and FT4 cohesion (FT4), 
which represent the aspects of powder dynamic, dynamic-static and static flowability. 
However, at least 200 gram of powder is required for the above measurement, which is 
not feasible for us due to the lack of drug raw material. For this reason, a simple angle 
repose test was conducted by the Powder Tester (Hosok Awa Micron Corporation), in 
order to find some differences between various formulations.
49
HNA, fine and large lactose and two formulations of mixture were prepared for the angle 
of repose test. 50 gram of powder was made for each sample, which was measured at 
least four times, and an average value was obtained as the repose angle.
4.2.3 Morphology Study of Formulations
The particle shape has an effect on powder flowability. Generally, the powder with ideal 
spherical shape will have perfect flowability without considering the interaction affect 
between individual particles. On the other hand, the crystalline powder with irregular 
shape could be poorly flowable, but some ultrafine particles maybe enhance the 
flowability by adhering to the larger particles. In order to find the relationship between 
particle morphology and drug delivery performance, the surface properties of different 
powder were studied using the scanning electron microscopy (SEM). Pure HNA, fine 
lactose, large lactose, mixture of HNA and fine lactose, and mixture of HNA and large 
lactose were prepared and observed by SEM, respectively.
4.2.4 Dose Uniformity
Fine lactose was used to evaluate the dose uniformity of the blister. According to the 
description of filling process in Chapter 3, 10 blisters were prepared, and the weight 
obtained was recorded as the total dose amount, from which we can get the average 
amount for each dose. The test was duplicated three times, and the variance was 
calculated.
4.2.5 In  Vitro Evaluation Test by ACI
A simulated lung deposition was used to evaluate the drug delivery efficiency in vitro for 
DPI. Using Anderson Cascade Impactor (ACI) or Next Generation Impactor (NGI),
50
particles with different size were calculated as fraction deposition in different part of lung 
tissue, where a fine powder fraction (FPF) was measured for the deposition of particles 
smaller than 4.7 pm, as a main evaluation parameter for the drug delivery efficiency.
In this experiment, two formulations, a mixture of HNA with fine lactose and large 
lactose, were tested using ACI. For each formulation, 6 blisters were prepared and given 
into the instrument (as shown as Figure 4.1). The air flow rate was controlled at 28.3 
LPM by a vacuum pump (Copley Scientific, HCP5), and each dose was released directly 
into the throat pipe of ACI, no spacer was used. Both distributions of HNA and lactose 
were calculated.
Figure 4.1 The in  v itro  evaluation test for DPI using ACI.
4.2.5.1 Measurement Method for HNA
HNA was determined by ultraviolet-visible spectroscopy (Agilent UV-visible 
spectroscopy 8453), using mixture of water and methanol (1:1) as solvent. A sample of 
HNA solution was scanned by the UV from 800 nm to 200 nm to determine the suitable 
wave length. Then a series of standard HNA solutions were prepared the calibration
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curve at this wave length. Briefly, 0.552 mg of HNA was dissolved into 100 mL of 
solvent as the stock solution. Then 0.01 mL, 0.02 mL, 0.04 mL, 0.06 mL, 0.08 mL and 
0.10 mL of stock solution were diluted into 10 mL with solvent as standard solutions, 
respectively. Using the solvent as blank, each standard solution was measured by UV 
spectrometer at 252 nm, the absorption was recorded, and a working curve was 
determined by plotting concentration to the absorption.
4.2.5.2 Measurement Method for Lactose
Lactose was determined by HPLC method, with the following method parameters: 
Waters 1525 Binary HPLC Pump, Waters 717 Plus Autosampler, Waters 2414 Refractive 
Index Detector, Waters Spherisorb® NH2 column (5 pm, 4.6 x 250 mm Analytical 
column), column temperature 30 °C, mixture of acetonitrile and water (at ratio of 4:1) as 
mobile phase, flow rate 1.0 mL per minute. To construct a working curve, 18.70 mg of 
lactose was dissolved into 100 mL of mixture solvent (water: methanol at 1:1) as the 
stock solution. Then 0.1 mL, 0.2 mL, 0.4 mL, 0.6 mL, 0.8 mL and 1.0 mL of stock 
solution were diluted into 10 mL using solvent as standard solutions, respectively. 20 pL 
of each standard solution was injected into HPLC, and the peak area was recorded. A 
calibration curve was obtained by plotting the peak area versus concentrations of standard 
solutions.
4.2.5.3 In  Vitro Evaluation by ACI
Two formulations, containing mixture of HNA with fine lactose and large lactose, were 
loaded into old DPI. 10 blisters of each formulation were prepared and given into ACI, 
each stage of the impactor was washed using mixture of water and methanol (1:1) and the 
volume of the solution was recorded to calculate the amount of HNA and lactose. Then
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concentration of HNA was measured by UV and lactose by HPLC. Particle deposition 
and fine particle fraction (FPF) were obtained. The weight changes of every blister were 
recorded before and after the test, which were considered as the emitted dose amount. 
Compared with the average loading dose amount, an emitted efficiency (EE, the ratio of 
emitted dose amount to average loading dose amount) could be calculated. Each test 
was repeated twice, and an average value was gained through three results.
4.3 Results and Discussion
4.3.1 Particle Size and Distribution
As indicated in Figure 4.2, the particle size and distribution of HNA, two types of lactose, 
and two formulations containing HNA and different lactose, were obtained by PSDA. 
The volumetric geometric diameter of particle was measured to determine the distribution 
graph, and D (4, 3) was calculated as the mean dynamic particle size.
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Figure 4.2: Particle size and distributions of the HNA, lactose and formulations: (a) 
fine lactose, large lactose and pure HNA; (b) formulation containing HNA and different
type of lactose.
According to Figure 4.2 a, the fine lactose used as carrier in the DPI showed a relatively 
narrow size distribution in two ranges, l-4pm and 30-70|im, leading to a 23.4 pm of 
geometric particle size (D (4, 3)). Some larger particles were detected in this fine powder, 
which contributed to the volumetric distribution in the range larger than 30pm, but most 
particles were smaller than 4pm. On the other hand, the large lactose showed a reverse 
narrow distribution. Most particles are larger than 100pm, combined with many smaller 
particles resulting in an average particle size as 156.8pm. The powder of pure HNA was 
composed of fine powder smaller than 40pm, most of which are around 3 pm. But
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So as to formulation 1 containing HNA and fine lactose, the mean geometric particle size 
was measured as 23.7 pm and the particle size distribution did not change too much from 
the fine lactose (Figure 4.2 b). The difference we can observe is that the lightly decreased 
amount of particles larger than 50 pm and smaller than 4 pm, which was probably due to 
the blending process. When the two powders were mixed using the coffee grinder, some 
larger particles could be broken and meanwhile, many small particles would adhere to the 
larger ones, but the mean particle size will not change considerablely. While the 
formulation composed by HNA and large lactose showed more considerable changes. 
The mean particle size of this formulation was reduced to 89.3 pm, because a larger 
amount of fine powder of HNA was added into larger lactose, and another reason may be 
the grinder process broke numerous particles larger than 110 pm.
4.3.2 Angle of Repose
The results of the angle of repose test of different powders are listed in Table 4.1, all the 
four batches of tests showed consistent results (the standard deviation were less than 0.3). 
As a result, the pure HNA powder could not be completed through the measurement 
process because all the powder jammed on the feeding mesh due to the poor flowability. 
Comparing the two types of lactose, the larger one showed much better flowability (mean 
repose angle was 37.48 ) than the smaller one (51.60 ). Similar to the particle size and 
distribution tests, the addition of HNA to different lactose showed different effects. The 
repose angle (51.60 ) for formulation 1 containing HNA and fine lactose was the same as 
that for fine lactose powder, but the formulation 2 consisting HNA and large lactose 
showed a much larger repose angle (43.10 ) than that of large lactose powder. All of these
because of the poor flowability, the mean geometric particle size of pure HNA was
16.0pm.
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results indicated that the addition of lactose could considerablely enhance the flowability 
of drug powders, especially the larger lactose would hopefully be of benefit to the 
improvement of powder characteristics of drug formulation, when the right amount of 
lactose was used as a carrier.
Table 4.1 Angle of Repose results for different powders
Formulation Test 1 Test 2 Test 3 Test 4 Average SD
HNA NA NA NA NA NA NA
Fine Lactose 51.90 51.30 51.70 51.50 51.60 0.26
Large Lactose 37.30 37.70 37.40 37.50 37.48 0.17
HNA + Fine 
Lactose 51.60 51.70 51.80 51.30 51.60 0.22
HNA + Large 
Lactose 43.30 43.00 42.90 43.20 43.10 0.18
4.3.3 Observation by SEM
Figure 4.3 illustrates the results obtained by SEM with different powder, including HNA, 
fine lactose, large lactose, a mixture of HNA with fine lactose, and a mixture of HNA 
with large lactose. According to Figure 4.3 a, two different types of particles could be 
observed through SEM, which contribute to the two peaks appearing in the particle size 
distribution test graph. One type of particle was as large as 20 pm, surrounded by another 
type of small particles with particle size around several microns. Similar to the result of 
particle size, the majority particles were around 3 pm. So regarding the fine lactose, 
Figure 4.3 b, besides two major types of powder, there were some larger particles (around 






Figure 4.3: SEM observation of Lactose and formulations: (a) pure HNA; (b) fine 
lactose; (c) large lactose; (d) formulation 1 (HNA with fine lactose); (e) formulation 2
(HNA with large lactose).
After mixing HNA with fine lactose, the grind process changed the powder a little bit, as 
shown in Figure 4.3 d. Few large particles (close to 50 pm) could be found, which means 
those particles maybe broken by the grinder into the majority large particles (around 20 
pm), and this result was similar to that obtained by particle size distribution test.
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The surface characteristics of larger lactose could be described by Figure 4.3 c. Most 
particles showed a particle size between 150 - 200pm, and some small particles could 
also be observed surrounding the larger ones. When the large lactose was mixed with 
HNA powder, the morphology changed as Figure 4.3 e. A big amount of particles around 
100pm could be found, which was supposed to be ground from large lactose particles. 
Also, smaller particles less than 10pm were observed to surround the larger ones. This 
photo could lead to the similar result to the particle size and distribution test.
Dose number
Figure 4.4 Dose uniformity test.
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4.3.4 Dose Uniformity
Figure 4.4 displays the results of dose uniformity test for old DPI. The average dose 
amount for fine lactose by hand filling was around 0.7 mg, the difference between every 
dose was no more than 0.04 mg. And the three batches of tests showed a good 
consistency, with standard deviation less than 0.06 mg. This result proved that the filling 
process is practical and qualified for drug delivery by DPI.
4.3.5 In  Vitro Evaluation by ACI
4.3.5.1 Measurement Method for HNA
A series spectrum of HNA with different concentrations were obtained by scanning 
within the wave length ranging from 200 nm to 900 nm, as shown in Figure 4.5 a. Two 
main peaks could be defined at 218 nm and 252 nm. The length of 252 nm was selected 
as the measurement wavelength, which could avoid the interference of many excipients. 
Figure 4.5 b shows the spectra of some HNA samples obtained from in vitro evaluation 
by ACI, with absorptions between 0.1~1.0 (UV spectroscopy shows good performance in 
this range). A standard curve was built up by plotting concentrations versus UV 
absorption, as shown in Figure 4.6. A good linearity correlation was obtained (r = 
0.99972). A linear equation was obtained from the plot, and listed in Table 4.2.
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a
Figure 4.5: Scanning spectrum of HNA from 200 nm to 900 nm.
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Table 4.2 Information of calibration curve of HNA.
Parameters value
Number of Standards 6
Calibration Curve C = k1 * A
Coefficient k1 5.5768E-3
Std.Dev. of k1 4.1931 E-5
Std.Dev. of Calibration 6.1468E-5
Correl. Coeff. (RA2) 0.99972
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4.3.5.2 Measurement Method for Lactose
Figure 4.7 showed HPLC spectra of lactose standard solution and a sample obtained from 
in vitro evaluation test by ACI. As shown in Figure 4.7 a, with the current HPLC method, 
a good shape peak could be recorded by HPLC at retention time around 14 minutes. The 
lactose in samples from evaluation test could also be detected (Figure 4.7 b).
A linear regulation was conducted. Excellent correlation was obtained between 
concentration and peak area (r 2 = 0.9991). The regulation equation is given below:
Equation 4.1




Figure 4.7: The HPLC graph of lactose: (a) lactose standard solution; (b) lactose sample
obtained from in vitro evaluation test.
Figure 4.8: Calibration curve of lactose by HPLC method.
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4.3.5.3 In  Vitro Evaluation by ACI
Figure 4.9 illustrates the particle deposition distribution results of HNA and two types of 
lactose in the in vitro evaluation test of old DPI using ACI. For the formulation 1, which 
contains HNA (Figure 4.9 a) and fine lactose (Figure 4.9 b), both powder showed similar 
distribution in different stages of ACI. There was almost 10% of powder deposition in the 
throat pipe and the connection between ACI and DPI (defined as stage O'), which 
represented the mouth cavity and throat of humans. Most drug and lactose particle 
occurred in stage 0, which contribute approximately 50% distribution. No considerable 
difference could be observed in deposition of stage 1 to 3, with a percentage between 5% 
and 10%. The particle with diameter larger than 4.7 pm could be cut off by stage 3, and 
the smaller ones would reach further stages. All the powder collected from stage 4 -9 was 
summarized and considered as fine powder fraction (FPF) of this formulation in ACI. As 
a result, the FPF of HNA was 13.69% while that of lactose was 17.94%. The emitted 
efficiency of formulation lfor HNA and lactose was 98.05% and 76.09%, respectively.
According to the above evaluation data, formulation 1, containing HNA and fine lactose 
could be efficiently delivered by the old DPI. The same distribution of HNA and lactose 
indicated that the mixture process was practical and qualified to prepare uniform drug 
powder formulation for the DPI, which was similar to the results of dose uniformity tests. 
However, both HNA and fine lactose showed a quite low FPF, with more than half 
amount of particle deposition in mouth, throat and upper airways. The probable reason 
might be that there was no considerable difference between HNA and fine lactose after 
the grinding process, or there was an extremely strong interactive force between those 
two types of particles, or the dispersing principle design of the DPI was not efficient 
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Figure 4.9: Particle deposition distribution of formulation 1 in in vitro evaluation of old DPI 
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Figure 4.10: Particle deposition distribution of formulation 2 in in vitro evaluation of old 
DPI: (a) distribution of HNA, and (b) distribution of large lactose.
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The results of in vitro evaluation of DPI using formulation 2 are described in Figure 4.10. 
Both HNA and large lactose showed the same trend and the major part (around 60%) of 
particles were detected at stage 0. It confirmed the results reported by some researchers 
that inhaled particles with a size larger than 10 pm will impact the upper airways, and 
only smaller particles could reach the deep lung tissue and deposit in the 
tracheo-bronchial airways and alveolar regions [64], Considering these fine powders, the 
FPF for HNA and large lactose were only 8.77% and 1.68%, respectively. There was a 
relatively large difference between the deposition distribution of HNA and large lactose 
powder in stage 1 (14.12% vs. 26.69%), partly because of a great amount of particles in 
large lactose powder. The emitted efficiency of formulation 2 for HNA and large lactose 
was 92.45% and 78.30 %, respectively.
Compared with formulation 1, the formulation prepared by larger lactose showed lower 
delivery efficiency by the old DPI, although there was no considerable difference 
between the emitted efficiency of the two formulations. It was reasonable that the FPF for 
larger lactose was much lower than fine lactose, which also could be explained by the 
results of particle size and distribution test and morphology study. But the much lower 
FPF of HNA turned to be a big challenge for formulations using larger lactose as carrier, 
because based on this experiment, the small drug particles could not be efficiently 
separated from the carriers during the dispersing process.
4.4 Conclusions
The research was to investigate the in vitro drug delivery performance of the old DPI. 
Aspects on both the formulation and device were taken into account. Two drug 
formulations were prepared by HNA and two types of lactose using a coffee grinder. The
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results for the formulation characterization, including particle size and distribution, angle 
of repose and morphology study, indicated that drug powder could be prepared by this 
simple method, and the larger lactose could considerablely improve the flowability of the 
powder, which probably was a promising advantage during the dry powder inhalation 
process. The dose uniformity test proved that this hand filling process was also qualified 
in a lab-scale level.
This study also investigated the powder deposition by ACI for the two formulations. The 
distribution of both HNA and lactose indicated that around 50% of particles would settle 
in mouth cavity, throat and upper airways, and no more than 20% of particles could reach 
the deep lung tissue as the fine powder. Although the larger lactose showed more benefits 
on the formulation characteristics, it led to a much lower FPF in the deposition test than 
that of fine lactose.
As a result, the formulation containing HNA and fine lactose was considered as the 
suitable formulation for the old DPI, which provided good dose uniformity, high emitted 
dose efficiency (98.05%) and relatively low FPF (13.69%).
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CHAPTER 5




According to the in vitro evaluation and formulation characterization tests in Chapter 4, 
the old DPI showed good dose uniformity and high emitted efficiency, but provided 
relatively low FPF with formulation containing HNA and lactose. It was probably caused 
by two aspects, the device design and the powder formulation characteristics.
The structure of DPIs, which could considerablely affect drug delivery performance, 
usually includes several issues, such as the mechanism for carrying the drug powder 
(actively or passively), the dispersing principle, and the storage method for the 
formulation in the reservoir. As we mentioned in Chapter 3, for the old DPI, a 
compressed air generated by the cylinder could pass through a paper filter in the blister to 
carry the drug formulation to the mouth piece. During this process, the powder plug, 
which was pushed out of the dose hole, could only disperse within the channel by a 
simple diffusion process. So the powder could perhaps not be efficiently de-agglomerated, 
especially for the powder bulk which was deposited into the dose hole with a higher 
density. Another major limitation for the old DPI is the design of the blister. The blister 
applied in this device was not a well designed package, and therefore could not provide 
an efficient protection from the moisture in the environment during a 2 weeks' treatment 
duration. A critical issue during the development of DPIs, should therefore be to keep the 
drug powder formulation stable and exihibit good flowability. Thus, a novel blister 
should be designed to be well sealed and, easily opened in the device while ensuring that 
drug powder formulation could be effectively carried out during the inhalation process.
In regards to the formulation aspect, the powder characteristics of drug and carriers, 
combine with the interaction forces between the two types of particles, could affect the 
dispersing performance. The formulation consisting of HNA and fine lactose showed
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better drug delivery performance, while the formulation with large lactose provided 
relatively better powder characteristics, which could probably benefit the dose filling 
consistency, drug formulation stability or even the drug delivery performance due to an 
improved dispersing principle. Therefore, the formulation should be considered along 
with the device design, and a balance should be made to ensure an optimized 
performance of the DPI.
In this research, a new DPI, as well as a new design of blister, was built. It contains a 
larger dose amount than the old one, and could be well sealed by pharmaceutical 
packaging materials leading to a good protection from the moisture in the environment. 
Formoterol, selected as the new drug model, and two types of lactose (fine and big) were 
also used as carriers to optimize the formulation characteristics. The drug delivery 
performance was investigated by in vitro evaluation test using ACI and NGI. A drug 
loading process was also developed and the dose uniformity was tested using different 
formulations.
5.2 Experimental Methods
In the experiment, due to the lack of drug raw material (Formoterol), fine lactose was 
combined (at ratio of Formoterol : lactose = 2:38) in order to complete the jet milling 
process. This product was considered for the evaluation test of new DPI.
5.2.1 Particle Size and Distribution
The particle size and distribution of Formoterol and the jet milled mixture with fine 
lactose (ForMix) were tested by PSDA. Each sample was measured three times for 
statistical accuracy.
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5.2.2 Observation of Formulation by SEM
In order to describe the differences between Formoterol and ForMix, both powders were 
prepared and observed by SEM, respectively.
5.2.3 Dose Uniformity
The three powders were used to evaluate the dose uniformity of the new blister by hand 
filling. According to the description of filling process in Chapter 3.5, six blisters were 
prepared, each dose was sucked out by a small tube connected to vacuum, and the weight 
obtained was recorded for every dose.
5.2.4 In  Vitro Evaluation Test by ACI and NGI
For comparison of two generations of DPIs, two formulations containing HNA and 
different size lactose were tested using new DPIs by ACI and NGI. The deposition 
distribution of HNA was obtained, and FPF was calculated.
For further evaluation of new DPIs, two formulations containing ForMix and different 
lactose were measured by AIC and NGI. The method for ACI test was similar to that 
described in Chapter 4.2.5. For NGI, 6 blisters were prepared and given into the 
instrument (as shown as Figure 5.1). The air flow rate was controlled at 60 LPM, and 
each dose was released directly into the inlet of NGI, no spacer was used. Both 
distributions of drug and FPF were calculated.
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Figure 5.1 The in  vitro evaluation test for DPIs using NGI.
5.2.4.1 Measurement Method for Formoterol
Formoterol was determined by HPLC. The device is composed of: Waters 1525 Binary 
HPLC Pump, Waters 717 Plus Autosampler, Waters 2414 Refractive Index Detector, 
Waters C l8 ODS column (5 pm, 4.6 x 250 mm Analytical column), column temperature 
30 °C, the mixture of acetonitrile and phosphate buffer solution (pH value 3.1, at ratio of 
22:78) as mobile phase, flow rate 1.0 mL per minute. To construct a standard curve, a 
stock solution was prepared by dissolving 40.00 mg of Formoterol into 100 mL of 
mixture solvent (water : methanol at 1:1). Then 0.05 mL, 0.1 mL, 0.2 mL, 0.4 mL, 0.8 
mL, 1.6 mL and 2.4 mL of stock solution were diluted into 10 mL using mixture solvent 
as standard solutions, respectively. 20 pL of each standard solution was injected into the 
HPLC, and the peak area was recorded. To plot the peak area to concentrations of 
standard solutions, a standard curve was obtained.
5.2.4.2 In  Vitro Evaluation by AC I and NGI
Two formulations, containing mixture of HNA with fine and large lactose, were loaded 
into new DPI. 6 blisters of each formulation were prepared and fed into ACI, each stage 
of the impactor was washed using mixture of water and methanol (1:1) and the volume of 
the solution was recorded to calculate the amount of HNA. The concentration of HNA
was measured by UV. Particle deposition and fine particle fraction (FPF) were obtained. 
The weight changes of every blister (n = 3) were recorded before and after the test, which 
were considered as the emitted dose amounts.
For the evaluation test using NGI, formulations containing HNA and ForMix, with 
different lactose carriers, were prepared. 6 blisters were delivered by new DPI into the 
NGI, and each plate and mesh was washed by solvent (mixture of methanol and water at 
ratio of 1:1). HNA in the sample solution was measured by UV and Formoterol by HPLC. 
The distribution of drug was calculated and FPF was obtained.
5.3 Results and Discussion
5.3.1 Particle Size and Distribution
Figure 5.2 illustrates the particle size and distribution of Formoterol raw material and 
ForMix obtained by PSDA. Volumetric geometric diameter of particle was evaluated to 
build up the distribution graph, and D (4, 3) was calculated as the mean dynamic particle 
size.
As described in Figure 5.2, Formoterol raw material was composed of small particles 
with particle size around 2 pm, some larger particles ranging from 10 - 20pm, and very 
few ones over 20 pm, resulting in an average particle size D (4,3) of 18.60 pm. As the 
drug ingredient, the particle size was too large for the efficient deposition of powder in 
deep lung tissues, so this raw material was ground to reduce the powder particle size to 
around 5 pm.
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Figure 5.2: Particle size and distributions of the Formoterol and ForMix.
When the Formoterol was jet milled with fine lactose at the ratio of 2:38, the product 
showed a different particle size and distribution. A very narrow distribution was obtained, 
most particles were at the range of 1 - 10pm and no particles were larger than 20 pm, and 
as a result, the average diameter D (4, 3) was 6.40 pm. This particle size was close to the 
limit of powder produced by jet mill.
5.3.2 Observation by SEM
Figure 5.3 displays the morphology of different powder, such as pure Formoterol powder 
and Formoterol jet milled mixture with fine lactose (ForMix).
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According to Figure 5.3 a, a large amount of cylindrical Formoterol crystals could be 
observed in the powder. Most of the crystals exhibit similar diameter, around 20 pm, with 
numerous fine particles attaching to the surfaces. The shape of the crystals and the 
narrow particles size distribution may contribute to the poor flowability of the pure drug 
powder, which was a big challenge for drug delivery by DPIs, especially the larger 
diameter. So the Formoterol raw material was jet milled with fine lactose due to the lack 
of pure drug powder. Compared with the product prepared by jet mill, the ForMix 
exhibited a similarly uniform and narrow particle size distribution. It could be observed 
from Figure 5.3 b that most particles were cut down to small fragments with diameter less 
than 10pm. Those segments were surrounded by numerous ultrafine particles. Combining 
with the result of particle size and distribution test by PSDA, this jet milled product could 
be considered as one kind of powder, as defined as ForMix, which showed uniform 
characteristics. All the micrographs obtained by SEM showed coincident results with that 




Figure 5.3: SEM observation of Formoterol and different formulations: (a) pure
Formoterol; (b) ForMix;
5.3.3 Dose Uniformity
Figure 5.4 a, b, c illustrates the dose uniformity test results using three different powders: 
HNA with fine lactose, HNA with large lactose and ForMix. As a result, the average dose 
amount for formulation containing HNA and fine lactose was around 0.90 mg, but most 
SD between doses and batches were larger than 0.10, some of them even more than 0.15, 
leading to a worst dose uniformity for the three powder formulations. The addition of 
large lactose as carrier enhanced the flowability of the formulation, therefore increased 
the dose uniformity of the powder considerablely. As listed in Figure 5.4 b, all the SD 
values were decreased to no more than 0.1. There was no considerable difference for the 
dose uniformity within and between batches.
Although the ForMix exhibited small powder particle size and narrow distribution, the 
dose uniformity test of this powder provided a qualified result. From Figure 5.4 c, it was 
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Figure 5.4 Dose uniformity test results for different formulations: (a) HNA with fine 
lactose; (b) HNA with large lactose; (c) ForMix (Formoterol jet milled with fine lactose).
consistency. No SD value was larger than 0.9. All the above dose uniformity test results 
revealed that the hand filling process was practical, but not suitable for all the 
formulations. Formulations with large lactose and Formoterol formulations could be 
successfully filled by this simple process.
5.3.4 In  Vitro Evaluation by ACI and NGI
5.3.4.1 Measurement Method for Formoterol
A series standard solutions of Formoterol were injected into the HPLC, and the 
chromatograph graph was recorded in Figure 5.5 a. The peak representing Formoterol 
was obtained at retention time around 4 min. The sample obtained from in vitro 
evaluation test was also measured by HPLC under the same condition, and the results are
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displayed in Figure 5.5 b. A considerable peak could be found at the similar retention 
time. A standard curve shown in Figure 5.5 c exhibited a good linearity (r 2 = 0.9997) 
between the concentration and peak area. An equation was obtained from the standard 
curve, and described below:
A = 7559.8 XC  + 4125 (5-1)
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Figure 5.5: Chromatograph graph and Calibration curve of Formoterol by HPLC method 
(a) standard solution of Formoterol; (b) sample solution of Formoterol; (c) calibration
curve.
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5.3.4.2 In  Vitro Evaluation of New DPI
Figure 5.6 illustrated the particle deposition distribution results of formulations 
containing HNA and two types of lactose in the in vitro evaluation test of new DPI using 
ACI. All the FPF and Emitted efficiency results for different formulations were 
summarised in Table 5.1. For the formulation using fine lactose as carrier, more than 40% 
of powder was detected in stage O’, which indicated that almost half powder formulation 
could be impacted in the mouth cavity, throat and upper airway of patients. Approximate 
10% -20% of powder deposition was obtained in stage 0 and 1, while 15.59% (FPF) of 
drug reached the deep lung tissue as fine powder. Compared with the FPF value of old 
DPI (13.69), there was only a little increase in the drug delivery performance. 
Additionally, there was a minor increase in the emitted efficiency of new DPI (98.66%) 
compared to the old one (98.05%). As a result, the new DPIs could efficiently deliver the 
formulation containing HNA and fine lactose, but only minor advances with this 
formulation were achieved compared to the old DPI.
According to Figure 5.6 b, the addition of large lactose as carrier brought considerable 
changes on the particle deposition of HNA in ACI evaluation test. Much less particles 
(almost 16%) were deposited on stage O’, and a little more powder was observed in the 
following three stages (stage 0 - 2). Much more particles could be found from stage 3 - 6 ,  
no considerable differences were found in the last two stages. Compared to the old DPI, 
for the same formulation, this new device provided a considerable increase in drug 
delivery performance from 8.77% to a higher FPF up to 21.19%, while a slight decrease 
of emitted efficiency from 92.45% to 88.18%. All these results demonstrated that our 
new designed inhaler showed an improvement over the previous one, and the large 
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Figure 5.6: Particle distribution of different HNA formulations in vitro evaluation of new 
DPIs by ACI: (a) HNA with fine lactose, and (b) HNA with large lactose.
84
In order to confirm the above conclusions, the in vitro evaluation tests were conducted 
using NGI and the results were obtained in Figure 5.7 a and b. There was no considerable 
difference on particle deposition distribution found between the two formulations 
containing different type of lactose. Similarly, more than 40% of powder was collected 
from the pre-separator, and the deposition on stage 2-6 were in the range of 5% -10%, 
resulting in a FPF close to 51% for both formulations (51.06% for fine lactose and 51.89% 
for big one). While the emitted efficiency showed a big difference, 102.00% for fine 
lactose compared with 74.07% for big one. Compared to the results obtained from ACI, 
new DPI showed an improved drug delivery performance for both formulations when 
using NGI as the evaluation device, but besides the lower emitted efficiency, no other 
effects of the particle size of lactose could be determined.
Figure 5.8 a and b showed the further evaluation test results for the new DPI, using a 
new formulation containing Formoterol as model drug. Compared to the formulation 
containing HNA and fine lactose, due to the small particle size and narrow distribution, 
only 18.73% of ForMix powder was detected in stage O’ of ACI, less powder on stage 0, 
and much more on the stage 3 -6. The value of FPF, which represented the drug delivery 
performance, was as high as 31.80%, over two folds of that of formulation composed of 
HNA and fine lactose, and 1.5 folds of formulation with large lactose. The results 
obtained from NGI evaluation even showed a much better performance (Table 5.1). 
Although 28.10% of drug powder settled in the pre-separator, much more fine powders 
reached the lower stages and led to a FPF value up to 62.38%. The emitted efficiency 
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Figure 5.7: Particle deposition distribution of different HNA formulations in vitro 
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Figure 5.8: Particle deposition distribution of Formoterol in vitro evaluation of new DPIs:
(a)ACI, and (b) NGI.
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Table 5.1 Fine particle fraction (FPF) and emitted efficiency (EE) of different 
formulations in the in vitro evaluation tests.
Results
(%) HNA + fine lactose
ACI
HNA + large 
lactose ForMix







FPF 15.59 21.19 31.80 51.06 51.89 62.38
EE 98.66 88.18 99.70 102.00 74.07 87.50
5.4 Conclusions
In this research, the same formulation containing HNA and two types of lactose were 
used to evaluate the enhancement of drug delivery performance of the new DPI by in 
vitro tests. Both ACI and NGI were used to conduct the evaluation tests. The evaluation 
results of ACI showed that the new DPI could provide a much better drug delivery 
performance than the old version, with a considerable improvement of FPF from 13.69% 
and 8.77% to 15.59% and 21.19%, respectively. The NGI even gave a much better 
results of FPF value up to 51%.
So as to the aspect of formulation characterization, including particle size and 
distribution, morphology study and dose uniformity test, indicated that formulations 
could be prepared by this simple method, but only the formulation containing larger 
lactose could be successfully filled by the hand-filling process.
This research also investigated a new formulation containing Formoterol, prepared by jet 
milling process with fine lactose, to conduct a further evaluation test on the new DPI. As 
a result, this formulation was well prepared, and qualified for the hand-filling process. 
Especially, the new DPI showed a considerable increase of drug delivery performance for 
ForMix than that of formulation composed of HNA and large lactose. The FPF value
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Based on the research in Chapter 4 and 5, the comparison of evaluation tests for two 
generations of DPI indicated that new DPI showed better drug delivery performance with 
two formulations, including formulation containing HNA with large lactose and 
formulation composed of Formoterol and fine lactose. Both formulations could be 
prepared by the simple mixing process, as well as successfully loaded by hand filling 
method in the lab. All the results indicated a promising start for the development of new 
pulmonary drug delivery device. As we discussed before, the development of a new DPI 
usually focuses on two aspects, i.e. device design and the preparation of formulation. 
Efforts on both aspects would hopefully increase the drug delivery performance in 
several ways, for example, optimizing the dispersion principle of drug powder within the 
channel and/or at the exit of the mouthpiece, modify the resistance and air flow inside the 
device, improve the powder characteristics of drug formulation, and provide a better 
storage condition for the multiple units of formulations.
Therefore, in this research some attempts were conducted on the prototype device, new 
DPI. Firstly, the formulation containing Formoterol and fine lactose was treated by 
mixing more lactose in order to improve the flowability. Two different types of lactose 
were compared by the effect of particle size of carrier on the dose uniformity and drug 
delivery performance. Also two different methods were selected for the preparation of 
drug formulation, including mixing by coffee grinder and rotary blender, so as to find a 
better mixing method for the scale up level.
On the other hand, some modification of the new DPI was also made in order to optimize 
the design of the device. As we described in Chapter 3, the puncture and its structure 
were considered to be critical factors which could affect the emitted efficiency and/or
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powder dispersing process, therefore leading to different drug delivery performance. In 
this research the diameter of the opening of puncture was changed, and different air flow 
was also applied to compare the drug delivery performance.
6.2 Experimental Methods
In the experiment, the ForMix produced by jet milling was considered as drug powder 
because of the narrow particle size distribution. Then this mixture was mixed with fine 
lactose or large lactose to prepare different formulations using coffee grinder. The mixing 
process was similar to the work described in Chapter 4, section 4.2 Experimental 
Methods. Different mixing process, using rotary blender, was applied to prepare the 
formulation, in order to enhance the mixing performance and flowability of the powder. 
For the mixing process by rotary blender, 50 gram of powder formulation containing 
ForMix and large lactose at the ratio of 1:4 was placed into the cylinder of rotary blender 
and mixed for over 12 hours to ensure a complete mixing process.
6.2.1 Particle Size and Distribution
ForMix, Formulation 1 (ForMix mixed with fine lactose at ratio of 1:4), and formulation 
2 (ForMix mixed with large lactose at ratio of 1:4) prepared by coffee grinder and rotary 
blender were tested by Particle Size Distribution Analyzer, respectively. The particle size 
and distribution were obtained. Each sample was measured three times to ensure the test 
results be statistically accuracy.
6.2.2 Observation by SEM
In order to describe the difference between ForMix, formulation 1 and 2, all the powders 
prepared were observed by SEM, respectively.
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6.2.3 Dose Uniformity
The three powders were used to evaluate the dose uniformity of the new blister by hand 
filling process. According to the description of filling process in Chapter 3.5, six blisters 
were prepared, each dose was sucked out by a small tube connected with vacuum, and the 
weight changes obtained was recorded as every dose amount.
6.2.4 Evaluation of Filling Machine in Laboratory Research Level
A filling machine in laboratory research level was designed as described in Chapter 3.5. 
To evaluate the performance of the filling machine, four formulations were prepared, 
including formulation 1 containing HNA and fine lactose (1:4), formulation 2 containing 
HNA and large lactose (1:4), formulation 3 containing ForMix with fine lactose (1:4) and 
formulation 4 containing ForMix with large lactose (1:4). In addition, the formulation 4 
was made by two different methods, coffee grinder and rotary blender.
All the above formulations were loaded into the blister by the filling machine and the 
dose uniformity was measured by the same method in section 6.2.3, respectively.
6.2.5 In  Vitro Evaluation Test by Dose Content Uniformity
For DPIs, a target-delivered dose is specified by label claim, which was usually packaged 
or metered-dose of drug. And in many cases, the target-delivered dose is less than the 
label claim, because it is impossible for 100% of powder to be emitted from the blister. 
Therefore, according to United States Pharmacopeia (USP 32), a delivered dose content 
uniformity (DCU) is required for the approval of dry powder inhalers containing drug 
formulations (solution, suspension or powder). The DCU test was conducted by the
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apparatus described in Figure 6.1. The apparatus is composed of three parts, sampling 
chamber (Figure 6.1 a-1), flow rate control device (Figure 6.1 a-2) and a vacuum pump 
(Figure 6.1 a-3). The details of the sampling chamber were indicated in Figure 6.1 b. This 
chamber could be connected to the DPIs by a mouth piece adapter and the vacuum pump. 
With a filter paper, all the powder discharged from the DPIs was supposed to be collected 
in the cavity of this chamber. There was a sensor placed in the middle side wall of the 
chamber, which was used to monitor the pressure difference within and out of the
sampling chamber. With this pressure drop, the flow rate could be adjusted to an
expected value by the flow rate control device; also the vacuum supplying duration could 
be set up. This vacuum duration was set up to ensure that the flow rate, which produces 
the pressure drop of 4 kPa, could withdraw 4 L volume of air from the DPIs. This volume 
is close to the volume of a human nature breath.
For the delivered DCU test, the vacuum pump was turned on, and the flow rate control 
device was set up for a flow rate of 38 LPM to produce a 4 kPa of pressure drop. At this 
flow rate, the vacuum duration was set up at 90 seconds. Then connect the loaded DPI to 
the mouth piece adapter, discharge the DPI, and keep the device connected until to the 
end of vacuum duration. Then wash the sampling chamber carefully with mixture of 
methanol and water (1:1), including the paper filter and mouth piece, and record the
volume of solution. Then the discharged dose unit was cut off from the blister and
washed by fixed volume of mixture of methanol and water (1:1). And the mouth piece 
was also treated by the same method. Formoterol in the three sample solutions was 






Figure 6.1 The apparatus for dose content uniformity test: (a) set up of apparatus; (b)
details for sampling chamber [65],
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three different parts were calculated, and the total emitted dose was defined as entire dose 
minus the drug amount remaining in the blister.
The formulations containing ForMix and large lactose (1:4) prepared by coffee grinder 
and rotary blender were used for DCU test. For each test, six doses were given into the 
DCU apparatus, and the average value was obtained.
6.2.6 Modification of the Puncture of DPIs
To indicate the effect of opening size of the puncture on the drug delivery performance, 
the size of puncture was changed from 1.4 mm to 1.94 mm. The relationship between the 
flow rate and resistance was studied using the DCU test apparatus. A formulation 
containing HNA and large lactose (1:4) was applied to the DPI with different sized 
puncture, and DCU tests were conducted to reveal the changes of drug delivery 
performance.
6.2.7 Different Ratio of Drug and Carrier
The particle size of the carrier had been studied in this research in many aspects, and the 
large lactose showed advances over the small one. On the other hand, the ratio between 
drug and carrier maybe also affect the drug delivery performance. In order to optimize 
the effect of percentage of large lactose added as carrier, ForMix was mixed with large 
lactose at two different ratios, 1:4 and 1:9, using rotary blender. Both drug formulations 
were applied to DCU test by the same method as described in section 6.2.5.
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6.2.8 Stability Test of Formulation
To evaluate the performance of the newly designed blister for the storage of powder 
formulation in normally used conditions by patients in the clinic, a formulation 
containing HNA and large lactose (1:4) was prepared, loaded into the blisters, and sealed 
by the method described in Chapter 3. The blisters were placed in an environment with 
high moisture (RSH 75%) and high temperature (40 °C) for 7days. Then the blisters were 
tested by DCU test in the same method as described in section 6.2.5. The drug content 
distribution in different parts was obtained and compared with that of formulation on day 
0.
6.3 Results and Discussion
6.3.1 Particle Size and Distribution
Figure 6.2 showed the particle size and distribution of ForMix, and two formulations 
containing ForMix and different lactose, obtained by PSDA. Volumetric geometric 
diameter of particles was determined from the distribution graph, and D (4, 3) was 
calculated as the mean dynamic particle size.
As described in Figure 5.2 in Chapter 5, When the Formoterol was jet milled with fine 
lactose at the ratio of 2:38, the average diameter was given by D (4, 3) at 6.40 pm. When 
the ForMix was mixed with fine lactose by coffee grinder, many large particles with 
particle size between 10-30 pm occurred in the distribution graph, as indicated as Figure 
6.2. Meanwhile, the peak representing the particles with diameter around 2pm still keep 
the similar value to that in ForMix, which means that even though the small particles 
could attach to the surface of the larger ones after mixing, they could be easily separated 
during the measurement process within the PSDA. This phenomenon encouraged us very
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much for the promising dispersing principle in the new DPIs. The mean particle size of 
this drug powder formulation was 24.2 pm, which was quite close to that of fine lactose 
(23.4 pm, see Chapter 4). The light increase in particle size probably was due to the 
addition of smaller particles of ForMix, which caused worse flowability, or even a little 
bit agglomerate within the formulation.
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Figure 6.2: Particle size and distributions of different formulations: (♦ ) ForMix with 
fine lactose; (A) ForMix with large lactose by coffee grinder; (A )  ForMix with large lactose
by rotary blender.
On the other hand, the addition of large lactose into ForMix, changed the particle size and 
distribution (the mean particle size was 80.60 pm) considerablely. A large amount of 
particles around 100pm contributed to the huge peak in the volumetric distribution graph 
of this formulation. The big difference between these two types of particles led to a 
considerable enhancement of flowability of the drug formulation, which could be a 
promising benefit for the drug loading and delivery.
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When the formulation containing ForMix and large lactose was prepared by rotary 
blender, some differences were observed compared with that by coffee grinder. From 
Figure 6.2, it could be found that the peaks contributed by small particle around 2 pm and 
10 pm was decreased, and particles larger than 110 pm occurred in the formulation. As a 
result, the mean particle size of formulation made by rotary blender was 102.10 pm, 
which was much larger than 80.60 pm of that made by coffee grinder. The reason maybe 
that less larger particles were broken by the mixing process, due to a relatively mild 
mixing process of rotary blender.
6.3.2 Observation by SEM
The morphology properties of two different formulations containing ForMix (ForMix 
mixing with fine lactose and with large lactose by coffee grinder, respectively) were as 
indicated in Figure 6.3. As expected, the formulation powder showed apparent 
characteristics close to what kind of lactose added as carriers (Figure 6.3 a and b). For the 
formulation containing ForMix and fine lactose, lots of lactose particles with size around 
20 pm were observed, as well as a large amount of ForMix particles with smaller size 
adhering to the lactose particles. The ForMix particles contributed to the bridge effect 
between the lactose particles, because there was no considerable difference between the 
two types of powders. Thus some agglomerates could be found, which maybe the main 
disadvantages of fine lactose used as carrier. While ForMix was mixed with large lactose, 
this problem was solved very well. The larger lactose particles with diameter around 100 
pm were not easy to form aggregations, even mixed with fine powder, ForMix, with 
particle size as small as 6 pm. Those fine particles, adhering onto the surface of lactose 
crystals, could somehow enhance the flowability of the powder.
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Figure 6.3: SEM observation of Formoterol and different formulations: (a) ForMix 
with fine lactose; (b) ForMix with large lactose.
When the formulation containing ForMix and large lactose was prepared by rotary 
blender, the morphology of powder showed minor difference, as described in Figur 6.4. 
The particle size of the large crystal of lactose was much larger than that made by coffee 
grinder, and also showed a more irregular shape with many sharp edges and crystal 
structures. More smaller particles were observed to be adhering to the surface of carrier 
particles. This result confirmed the conclusion from the particle size and distribution test,
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that the rotary blender could be used as a mild method to prepare the drug powder 
formulation.
Figure 6.4: SEM observation of Formoterol mixed with large lactose by rotary blender. 
6.3.3 Dose Uniformity
Figure 6.5 showed the dose uniformity test results using two different powders: 
formulation 1 containing ForMix and fine lactose, and formulation 2 with large lactose. 
Compared to the dose uniformity result of ForMix in Chapter 5, the addition of fine 
lactose to the ForMix didn't improve the performance during the hand filling process 
(Figure 6.5 a). A considerable difference occurred in the average dose amount, which 
increased from ~0.7 mg of ForMix to -l.Omg of formulation 1. The SD both within and 
between batches were much larger with the addition of fine lactose. Combining with the 
results of powder characteristics results before, this formulation was proved to be no 
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Figure 6.5 Dose uniformity test results for different formulations: (a) ForMix with fine
lactose; (b) ForMix with large lactose.
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The addition of larger lactose as carriers could achieve a better dose uniformity than the 
fine lactose, as indicated in Figure 6.5 b. A much larger average dose amount (around 
1.40 mg) was obtained with this formulation and the SD both within and between batches 
was much smaller than that with fine lactose and ForMix. These results confirmed that 
the lactose with big particle size could be applied in the drug formulation as carriers, 
which could promisingly enhance the flowability and dose uniformity.
6.3.4 Evaluation of the Filling Machine in Laboratory Research Level
The results for evaluation of filling machine indicated that the formulations containing 
fine lactose as carriers could not be loaded by filling machine successfully. During the 
filling process, this powder could be loaded into the loading plate, but several doses could 
not be vibrated off from the loading plate into the blister, even though a stronger 
vibration was applied.
While, the formulations containing large lactose showed good results for the evaluation 
test, as indicated in Figure 6.6. According to Figure 6.6 a, approximate 0.7 mg of powder 
containing HNA and large lactose could be filled into the blister, with a small SD within 
batches (less than 0.08), but a relatively larger SD between batches (more than 0.1, and 
some up to 0.14). So as to the formulation containing ForMix and large lactose (Figure 
6.6 b and c), both powders prepared by different method showed a much better result. 
The average dose amount of these powder formulations was around 1.7 mg, and the SD 
within and between batches were all less than 0.1. With a lightly higher SD value within 
batches for the powder made by rotary blender, the preparation method did not give 
considerable difference on the dose uniformity test. Therefore, both methods were proved 
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Figure 6.6 Dose uniformity test results for different formulations: (a) HNA with large 
lactose 1:4; (b) ForMix with large lactose by coffee grinder; (c) ForMix with large lactose
by rotary blender.
6.3.5 In  Vitro Evaluation Test by Dose Content Uniformity
Formulation containing ForMix and large lactose at the ratio of 1:4 was prepared by 
coffee grinder for the DCU test, and the results of two tests were as described in Figure 
6.7. Both tests showed the similar results for the delivered dose performance. More than 
30% of drug content could be detected in the sampling chamber, and around 20% was 
obtained at the mouth piece, and the same amount of drug (20%) stay in the blisters. The 

















Figure 6.7: The DCU test result for formulation containing ForMix and large lactose at
ratio of 1:4 prepared by coffee grinder.
The effect of preparation method on the DCU test was indicated by Figure 6.8. 
Considerable difference was observed with the formulation made by rotary blender. 
Much more drug content (45.23 %) was collected in the sampling chamber for the 
formulation prepared by rotary blender comparing with 31.75% for the powder made by 
coffee grinder. There was only slight decrease of drug particles measured in mouth piece 
and remaining in the blister, with a minor enhancement of total delivered dose percentage 
from 80.44% to 83.77%. As a result, the rotary blender showed some benefits for the 
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Figure 6.8: The DCU test result for formulation containing ForMix and large lactose at 
ratio of 1:4 prepared by different method (coffee grinder and rotary blender).
6.3.6 Modification of Puncture of DPI
According to the description of DCU test, a pressure drop at about 4 kPa was required on 
the sampling chamber, which was used to simulate the nature breath conditions. 
Therefore, the value of air flow rate applied in the test system including the DPIs and 
DCU apparatus, would depend on the airflow resistance of the device, which was 
affected considerablely by the diameter of the puncture. When the puncture diameter was 
modified from 1.4 mm to 1.94 mm, the relationship between air flow, airflow resistance 
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Figure 6.9: Effect of puncture diameter on the air flow and DCU test result for 
formulation HNA : large lactose 1:4: (a) relationship between the puncture diameter, air 
flow, airflow resistance and pressure drop; (b) effect of puncture diameter on the DCU
test.
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resistance and pressure drop was affected by the puncture diameter considerablely. When 
the puncture was expanded with the diameter, the airflow resistance did not change too 
much at low air flow, for example 20 and 40 LPM. Briefly, when 20 LPM of air flow rate 
was applied, the pressure drop for both puncture was 1.5 kPa and 2.85 kPa, respectively. 
And at 40 LPM, the pressure drop was decreased from 7.83 kPa to 4.00 kPa with the 
increase of puncture diameter. The most considerable difference occurred at 60 LPM of 
air flow rate, it dropped dramatically from 33.84 kPa to 8.00 kPa, which means that at 4 
kPa of pressure drop during the DCU test, a much higher air flow rate could be applied 
on the instrument.
Like the relationship between air flow resistance and pressure drop, the DCU test results 
showed considerable changes with the modification of puncture diameter. From Figure 
6.9 b, we could conclude that all the parameters obtained from the new puncture were 
better than that from the old one. The percentage of drug collected in the sampling 
chamber was enhanced from 54.42% to 61.06%, and that in mouth piece was close with 
slight increase, 12.38% vs. 10.78%. The amount of drug powder remaining in the blister 
was dramatically decreased from 14.13% to 6.82%, which showed a considerable benefit 
of the modification of puncture diameter. In addition, with the expansion of puncture 
diameter, the total delivered dose percentage was increased from 85.87% to 93.18%. All 
the above results indicated that the expansion of puncture diameter was a promising 
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Figure 6.10: The effect of air flow resistance on the DCU test result for formulation 
containing ForMix and large lactose at ratio of 1:4 prepared by rotary blender.
Formulation composed of ForMix and large lactose at the ratio of 1:4 was prepared by 
rotary blender and used for the DCU test with different air flow resistance. As indicated 
in Figure 6.10, a minor difference was given by changing air flow resistance. When a 
higher air flow resistance was applied, 5 % more drug powder was detected in the 
sampling chamber, almost 6.5% and 4% less drug content were obtained in the mouth 
piece and blister respectively. So as to the total delivered dose percentage, a 4% increase 
was given with the middle air resistance over that with the lower one.
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Figure 6.11: The effect of drug carrier ratio on the DCU test result for formulation 
containing HNA and large lactose.
6.3.7 Different Ratio of Drug and Carrier
The effect of the amount of lactose added as carrier on the drug delivery performance 
was indicated in Figure 6.11. The modification of ratio of drug and lactose did not show 
considerable difference on the DCU test. For both formulations, there were around54% of 
drug detected in the sampling chamber and 14% of drug remaining in the blisters. 
Compared with formulation containing less lactose, more drug powder of formulation 
with larger API carrier ratio was found in the mouth piece, 17% vs. 10.78%. As a result, 
the total delivered dose performance for both formulations were comparative, given an 
value as high as 85%.
i n
Figure 6.12: DCU test result for formulation containing HNA and large lactose (1:4) in the
stability test.
6.3.8 Stability test of the Formulation
The powder containing HNA and large lactose (1:4) did not show any considerable 
difference after 7 days storage in the described conditions, as indicated in Figure 6.12. 
Almost 60% of drug content was detected in the sampling chamber for both powder 
formulations, and around 10% of drug powder was collected from the mouthpiece. The 
only relatively large difference occurred in the blister remaining of the drug powder. For 
the power after one week storage, more powder could stay in the blister units after the 
discharging operation, 12.48% vs. 6.82%, almost as twice as that in day 0. The total 




In this research, additional modifications on both device and formulation were conducted 
to evaluate the enhancement of drug delivery performance of the new DPI by in vitro 
tests. From the aspect of design of device, the expansion of puncture diameter from 1.4 
mm to 1.94 mm indicated great improvement on the drug delivery performance of 
formulation containing HNA and large lactose. With the dramatic decrease of air flow 
resistance of the device, a higher air flow rate was applied to produce a pressure drop of 
4 kPa, resulting in more than 7% increase of the total delivered dose percentage for the 
HNA formulation, while a 4% enhancement for formulation containing Formoterol.
The research of formulation design, including carrier size and distribution, morphology 
study and dose uniformity test, indicated that large lactose was much more suitable than 
fine lactose as carrier for formulation containing Formoterol. Especially for the new 
designed filling machine, only formulations containing large lactose as carrier could be 
successfully filled by the filling process described in this research. Different preparation 
method could affect the drug formulation and even the drug delivery performance. The 
formulation made by rotary blender showed some advantages over that by coffee grinder.
The study on the formulation containing HNA and large lactose indicated that the amount 
of lactose added into the formulation did not show considerable effect on the drug 
delivery performance. And the stability test results showed that the design of blister was 





Dry powder inhalers (DPIs) have been more and more widely applied in pulmonary drug 
delivery, because of their unarguable advantages over pMDIs and nebulizers, including 
ease of operating, good physical and chemical stability, accuracy and reproducible drug 
delivery, simple design and low cost and so on. There have been many DPIs in the 
current market, applying various powder dispersing principles, such as breath-activated 
or power-assisted (pneumatic, impact force and vibratory). However, for the current 
power-assisted devices, the structures are very complicated and the operation requires 
more cooperation of the patients, which could probably affect the drug delivery 
performance or reproducibility of treatment. Therefore, the passive DPIs with more 
simple structure and less cooperation of patient are the promising developments of 
pulmonary drug delivery devices.
The objective of this thesis was to develop a new DPI based on the previous research 
work on old device. To compare the drug delivery performance of two types of DPIs, 
various formulations were applied to the powder characterisation and in vitro evaluation 
tests. Associated with the device, a filling process and equipment in lab scale were also 
developed for the DPI. Meanwhile, to optimize the new DPI, additional modifications on 
both the device and drug formulations were conducted to study the effects on the 
pulmonary drug delivery performance.
As an active DPI, the old DPI was designed to deliver drug formulations with small 
dosage amount, using a compressed air generated by the cylinder to carry out the powder 
from the blister. A hand-filling process and reloading operation was proved to be 
qualified for the old DPI. Formulations containing HNA and two types of lactose could 
be prepared by this simple method, and the larger lactose could considerablely improve 
the flowability of the formulation. The drug delivery performance of the old DPI was
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evaluated by in vitro tests in this research. It was found that fine lactose provided a higher 
fine powder fraction than larger lactose as carrier for formulations containing HNA, even 
though the larger lactose showed considerable improvement on the formulation 
characteristics.
Based on the previous research of the existing device, a new DPI was successfully 
developed and characterized. This newly designed passive DPI showed unarguable 
advantages over the old one on aspects of both device and formulations. It was indicated 
that the new device provided a more simple structure, lower cost, larger dose amount, and 
easier operation. A promising improvement is the design of a well packaged blister, 
which could provide very good protection during storage condition, as well as 
convenience for reloading of blisters. In addition, an advanced filling machine in lab 
scale was developed to prove the potentiality of the filling method in industrial 
manufacturing process. The results of in vitro evaluation tests confirmed the 
improvement of drug delivery performance of the new DPI using the same formulation 
containing HNA and two types of lactose. For ACI test, the new DPI could provide a 
considerable enhancement of FPF from 13.69% and 8.77% to 15.59% and 21.19%, 
respectively. Using NGI, a much better results of FPF value up to 51% was obtained by 
the new DPI. The formulation containing Formoterol showed a best drug delivery 
performance during all the drug formulations, which FPF obtained by ACI and NGI was 
as high as 31.80% and 62.38%, respectively.
Additional modifications on both device and formulation were conducted to optimize the 
drug delivery performance of new DPI. It was proved that the expansion of puncture 
diameter from 1.4 mm to 1.94 mm could considerablely increase the drug delivery 
performance of formulation containing HNA and large lactose. As a result, an
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improvement of 7% was observed for the total delivered dose percentage. The 
formulation prepared by rotary blender showed advantages on that made by coffee 
grinder. While, the amount of lactose added to the formulation did not show considerable 
effects on the drug delivery performance of new DPI. In addition, the results of 
preliminary stability test indicated that the design of blister was qualified for the storage 
of drug powder formulation during normal use duration.
Based on the experiments conducted in this thesis, some further research work on the 
new DPI is planned to carry out in the next stage. For example, the design of the device 
should be optimized by modifications of the structure, including particle dispersing 
principle, powder entrain mechanism, dose metering system, and preparation method for 
blister. In addition, the effects of drug formulation characteristics on the drug delivery 
performance should be dedicated by investigations on the particle size and distribution, 
powder morphology, density, drug carrier ratio, and preparation method. Last but not 
least, the in vitro evaluation tests on the new device should be conducted following the 
procedure and guideline of Pharmacopeia of United States, which could hopefully 
accelerate the application and approval process of this product by FDA.
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Appendix A: Experimental Data and Errors
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In order to provide accurate data for analysis, most experiments in this research were conducted 
at least three times, the average value and standard deviations were calculated. For the dose 
uniformity test, more than 6 blisters, approximately 96 doses were tested, which provided the 
valuable results with statistic accuracy.
In chapter 4, three blisters were filled by fine lactose through the hand-filling process, and each 
dose amount was measured by recording the weight changes before and after the dose was 
removed from the dose units. The data and standard derivation were listed in Table Al.
Table A1: Measurements of dose uniformity for old DPI.
Average dose Test 1 Test 2 Test 3 SD
1 0.62 0.74 0.7 0.06
2 0.66 0.67 0.69 0.02
3 0.67 0.65 0.72 0.03
4 0.7 0.74 0.7 0.03
5 0.63 0.63 0.68 0.03
6 0.64 0.64 0.68 0.02
7 0.68 0.65 0.67 0.01
8 0.64 0.67 0.69 0.03
9 0.66 0.65 0.69 0.02
10 0.67 0.67 0.69 0.01
SD 0.02 0.04 0.01 0.01
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Two formulations containing HNA and different lactose as carrier were applied in the in vitro 
evaluation tests using ACI, the distribution of both HNA and lactose particles were listed in Table 
A2 to A5.
Table A2: Measurements of particle distribution of HNA in ACI test for formulation
containing HNA and fine lactose
Stage number 1 2 3 Average SD
O' 8.62 11.03 7.82 9.16 1.67
0 46.30 46.89 52.37 48.52 3.35
1 9.60 11.38 10.59 10.53 0.89
2 9.18 10.14 10.00 9.77 0.52
3 6.43 6.21 6.05 6.23 0.19
4 2.77 3.10 2.87 2.91 0.17
5 3.88 3.98 4.64 4.17 0.41
6 3.51 3.81 3.83 3.72 0.18
7 2.40 2.69 0.77 1.95 1.04
8 0.69 0.63 0.76 0.69 0.06
9 0.31 0.14 0.30 0.25 0.10
Total amount (mg) 30.44 29.00 29.74 29.73 0.72
Fine Particle Fraction (<4.7um) 13.56 14.35 13.17 13.69 0.60
Theoretical amount (mg) 30.92 29.86 30.18 30.32 0.54
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Table A3: M e a s u re m e n ts  o f  p a r t ic le  d is tr ib u t io n  o f  la c to s e  in  A C I te s t  f o r  fo rm u la t io n
c o n ta in in g  H N A  a n d  f in e  la c to s e
Stage number 1 2 3 Average SD
O' 8.53 8.73 8.11 8.46 0.31
0 48.74 47.86 48.30 48.30 0.44
1 9.61 9.47 9.71 9.60 0.12
2 8.24 7.73 8.96 8.31 0.62
3 8.21 7.29 6.69 7.39 0.77
4 3.17 3.55 2.99 3.24 0.28
5 4.51 5.49 6.28 5.43 0.88
6 3.97 5.16 4.01 4.38 0.68
7 2.69 3.20 2.84 2.91 0.26
8 1.75 1.07 1.68 1.50 0.37
9 0.57 0.44 0.43 0.48 0.08
Total amount (mg) 94.66 91.43 90.78 92.29 2.08
Fine Particle Fraction (<4.7um) 16.67 18.92 18.23 17.94 1.15
Theoretical amount (mg) 123.69 119.45 120.73 121.29 2.17
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Table A4: M e a s u re m e n ts  o f  p a r t ic le  d is tr ib u t io n  o f  H N A  in  A C I te s t  fo r  fo rm u la t io n
c o n ta in in g  H N A  a n d  la rg e  la c to s e
Stage number 1 2 3 Average SD
O' 7.00 6.20 7.32 6.84 0.57
0 64.41 61.54 59.93 61.96 2.27
1 14.44 15.17 12.73 14.12 1.25
2 4.61 5.61 7.95 6.06 1.71
3 2.07 2.28 2.43 2.26 0.18
4 1.19 1.06 1.12 1.12 0.07
5 1.69 1.90 2.31 1.97 0.32
6 2.02 2.97 2.66 2.55 0.48
7 1.96 2.51 2.81 2.42 0.43
8 0.43 0.56 0.55 0.51 0.07
9 0.19 0.21 0.20 0.20 0.01
Total amount (mg) 42.28 41.01 44.25 42.51 1.63
Fine Particle Fraction (<4.7um) 7.48 9.19 9.64 8.77 1.14
Theoretical amount (mg) 44.59 46.56 46.78 45.98 1.21
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Table A5: M e a s u re m e n ts  o f  p a r t ic le  d is tr ib u t io n  o f  la c to s e  in  A C I te s t  f o r  fo rm u la t io n
c o n ta in in g  H N A  a n d  la rg e  la c to s e
Stage number 1 2 3 Average SD
O' 5.16 2.77 2.48 3.47 1.47
0 66.77 56.21 55.56 59.51 6.29
1 21.75 30.55 27.76 26.69 4.50
2 3.87 7.93 11.61 7.80 3.87
3 0.75 0.81 0.99 0.85 0.13
4 0.43 0.27 0.44 0.38 0.10
5 0.27 0.38 0.28 0.31 0.06
6 0.22 0.31 0.34 0.29 0.06
7 0.27 0.28 0.24 0.26 0.02
8 0.22 0.19 0.17 0.19 0.02
9 0.29 0.30 0.13 0.24 0.09
Total amount (mg) 137.24 149.11 145.67 144.01 6.11
Fine Particle Fraction (<4.7um) 1.71 1.74 1.60 1.68 0.07
Theoretical amount (mg) 178.34 186.26 187.14 183.91 4.85
129
In chapter 5, three formulations were used for the dose uniformity test, formulation 1 containing 
H N A  and fine lactose, formulation 2 containing H N A  and large lactose and ForM ix com posed o f  
Form oterol jet m illed w ith fine lactose. For each formulation, 6 blister were filled and measured 
w ith the w eight changes. The average dose amount and standard deviations within and betw een  
blisters w ere listed from Table A 6 to A  8.
Table A6: Measurements of dose uniformity for new DPIs, using formulation containing
HNA and fine lactose.
Dose
Nmuber Blister 1 Blister 2 Blister 3 Blister 4 Blister 5 Blister 6 SD
1 0.68 1.06 0.84 0.89 0.91 0.63 0.16
2 1.15 0.85 0.88 0.99 0.77 0.99 0.13
3 0.94 0.91 0.93 1.00 0.90 0.87 0.04
4 0.86 1.05 0.92 0.93 0.76 0.89 0.09
5 0.92 0.96 0.94 0.97 0.66 0.82 0.12
6 0.92 0.95 0.99 1.04 0.76 0.96 0.10
7 0.93 0.93 0.93 0.99 0.80 0.87 0.07
8 0.97 0.67 0.63 0.73 0.98 0.85 0.15
9 0.90 0.88 0.91 0.99 0.75 0.92 0.08
10 0.89 0.77 0.79 0.97 0.90 0.69 0.10
11 0.96 0.94 0.85 0.93 0.78 0.86 0.07
12 0.99 0.84 1.01 0.96 0.90 0.82 0.08
13 0.91 0.96 1.05 0.81 0.90 0.97 0.08
14 0.89 0.91 1.01 0.95 0.87 0.89 0.05
15 0.99 0.96 0.96 0.91 0.95 0.96 0.03
16 1.01 1.01 0.88 1.10 1.04 0.84 0.10
Average
Dose 0.93 0.92 0.91 0.95 0.85 0.86
SD 0.10 0.10 0.10 0.09 0.10 0.10
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HNA and large lactose.
Table A7: M e a s u re m e n ts  o f  d o s e  u n ifo rm ity  f o r  n e w  D P Is ,  u s in g  fo rm u la t io n  c o n ta in in g
Dose
Nmuber Blister 1 Blister 2 Blister 3 Blister 4 Blister 5 Blister 6 SD
1 1.31 1.40 1.49 1.40 1.50 1.51 0.08
2 1.32 1.31 1.47 1.42 1.41 1.44 0.07
3 1.41 1.40 1.41 1.47 1.45 1.47 0.03
4 1.26 1.33 1.46 1.39 1.39 1.46 0.08
5 1.34 1.46 1.36 1.42 1.41 1.50 0.06
6 1.35 1.33 1.37 1.38 1.36 1.45 0.04
7 1.33 1.32 1.38 1.38 1.42 1.50 0.07
8 1.37 1.43 1.50 1.53 1.51 1.46 0.06
9 1.39 1.42 1.35 1.52 1.41 1.51 0.07
10 1.36 1.36 1.40 1.40 1.44 1.42 0.03
11 1.49 1.44 1.35 1.54 1.36 1.37 0.08
12 1.42 1.41 1.29 1.47 1.41 1.47 0.07
13 1.38 1.39 1.44 1.49 1.53 1.46 0.06
14 1.46 1.39 1.41 1.44 1.35 1.42 0.04
15 1.44 1.41 1.37 1.34 1.44 1.44 0.04
16 1.35 1.35 1.44 1.44 1.46 1.55 0.08
Average
Dose 1.37 1.38 1.41 1.44 1.43 1.46
SD 0.06 0.05 0.06 0.06 0.05 0.04
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ForMix.
Table A8: M e a s u re m e n ts  o f  d o s e  u n ifo rm ity  fo r  n e w  D P Is ,  u s in g  fo r m u la t io n  c o n ta in in g
Dose
Nmuber Blister 1 Blister 2 Blister 3 Blister 4 Blister 5 Blister 6 SD
1 0.78 0.74 0.58 0.62 0.77 0.75 0.08
2 0.78 0.69 0.68 0.7 0.6 0.67 0.06
3 0.75 0.74 0.62 0.57 0.71 0.76 0.08
4 0.65 0.74 0.65 0.73 0.73 0.69 0.04
5 0.75 0.75 0.75 0.76 0.69 0.69 0.03
6 0.78 0.72 0.69 0.7 0.74 0.65 0.04
7 0.79 0.57 0.71 0.72 0.67 0.65 0.07
8 0.73 0.65 0.64 0.76 0.62 0.62 0.06
9 0.69 0.7 0.71 0.76 0.73 0.75 0.03
10 0.75 0.78 0.61 0.65 0.78 0.7 0.07
11 0.75 0.62 0.58 0.61 0.79 0.77 0.09
12 0.73 0.74 0.65 0.63 0.84 0.78 0.08
13 0.75 0.73 0.73 0.6 0.65 0.74 0.06
14 0.77 0.77 0.69 0.69 0.69 0.7 0.04
15 0.77 0.65 0.62 0.63 0.73 0.73 0.06
16 0.68 0.62 0.64 0.76 0.64 0.75 0.06
Average
Dose 0.74 0.70 0.66 0.68 0.71 0.71
SD 0.04 0.06 0.05 0.07 0.07 0.05
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In chapter 5, to evaluate the enhancem ent o f  drug delivery performance o f  new  DPIs, the same 
form ulation were measured by ACI. The particle distribution were listed by Table A  9 and A  10.
Table A9: Measurements of particle distribution of lactose in ACI test for formulation
containing HNA and fine lactose
Stage number 1 2 3 Average SD
O' 48.79 42.28 38.05 43.04 5.41
0 11.89 17.92 12.22 14.01 3.39
1 16.59 21.25 19.31 19.05 2.34
2 7.03 8.67 9.35 8.35 1.19
3 2.82 3.40 3.79 3.34 0.49
4 4.10 5.55 5.94 5.19 0.97
5 4.75 5.61 6.12 5.49 0.70
6 3.00 4.24 3.93 3.72 0.64
7 0.74 0.95 1.01 0.90 0.14
8 0.28 0.26 0.28 0.27 0.01
Total amount (mg) 12.55 13.82 15.59 13.99 1.53
Fine Particle Fraction (<4.7um) 12.86 16.61 17.29 15.59 2.39
Theoretical amount (mg) 13.24 14.53 14.77 14.18 0.82
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Table A10: M e a s u re m e n ts  o f  p a r t ic le  d is tr ib u t io n  o f  la c to s e  in  A C I te s t  f o r  fo rm u la t io n
c o n ta in in g  H N A  a n d  la rg e  la c to s e
Stage number 1 2 3 Average SD
O' 22.27 14.55 10.94 15.92 5.78
0 15.80 15.81 15.08 15.56 0.42
1 25.18 23.74 23.24 24.05 1.01
2 13.37 14.53 14.76 14.22 0.74
3 7.34 9.36 10.47 9.06 1.59
4 6.80 9.18 10.66 8.88 1.94
5 4.37 7.64 7.69 6.57 1.90
6 3.29 3.37 4.44 3.70 0.64
7 0.72 1.07 1.59 1.13 0.44
8 0.86 0.77 1.13 0.92 0.19
Total amount (mg) 21.44 24.09 24.28 23.27 1.59
Fine Particle Fraction (<4.7um) 16.04 22.03 25.50 21.19 4.79
Theoretical amount (mg) 25.48 26.96 26.74 26.39 0.80
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For further evaluation o f  drug delivery performance o f  new  DPIs, NGI w as used to determine the 
particle distribution o f  formulation containing H N A  with different lactose and ForM ix. The 
particle distribution w as listed from Table A  11 and A  14. A s comparison, ForM ix w as also 
m easured b y  ACI, w hich w as described by Table A 13.
Table A11: Measurements of particle distribution of lactose in NGI test for formulation
containing HNA and fine lactose
Stage number 1 2 3 average SD
Pre-separator 44.74 42.69 41.06 42.83 1.84
1 5.98 7.10 5.23 6.10 0.94
2 8.55 7.60 7.14 7.76 0.72
3 10.50 9.80 8.98 9.76 0.76
4 11.33 9.01 9.40 9.91 1.24
5 7.27 9.56 10.10 8.98 1.50
6 4.95 6.18 8.16 6.43 1.62
7 3.30 4.54 5.60 4.48 1.16
8 3.40 3.51 4.32 3.74 0.51
Total amount (mg) 12.91 14.01 14.38 13.77 0.76
Fine Particle Fraction (<4.7 urn) 49.29 50.18 53.70 51.06 2.33
Theoretical amount (mg) 13.25 13.94 14.37 13.85 0.57
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Table A12: M e a s u re m e n ts  o f  p a r t ic le  d is tr ib u t io n  o f  la c to s e  in  N G I te s t  f o r  fo rm u la t io n
c o n ta in in g  H N A  a n d  la rg e  la c to s e
Stage number 1 2 3 average SD
Pre-separator 43.11 41.08 40.03 41.41 1.57
1 6.45 7.57 6.08 6.70 0.78
2 8.23 8.98 8.40 8.54 0.39
3 9.74 9.47 8.63 9.28 0.58
4 8.69 8.78 10.45 9.31 0.99
5 8.33 9.59 9.20 9.04 0.65
6 6.56 4.71 7.01 6.09 1.22
7 5.19 5.24 5.68 5.37 0.27
8 3.70 4.56 4.52 4.26 0.49
Total amount (mg) 16.89 20.27 20.63 19.26 2.06
Fine Particle Fraction (<4.7 urn) 50.44 51.34 53.89 51.89 1.79
Theoretical amount (mg) 26.34 25.24 26.98 26.19 0.88
Table A13: Measurements of particle distribution of lactose in ACI test for formulation
containing ForMix
Stage number 1 2 3 Average SD
O' 20.88 19.37 15.95 18.73 2.53
0 6.30 5.24 5.61 5.72 0.54
1 23.90 19.22 20.40 21.17 2.43
2 13.73 15.19 15.87 14.93 1.09
3 7.66 7.62 7.88 7.72 0.14
4 12.23 13.92 12.54 12.90 0.90
5 9.83 11.59 11.85 11.09 1.10
6 5.21 7.08 7.69 6.66 1.30
7 0.38 0.54 2.15 1.02 0.98
8 0.00 0.21 0.17 0.13 0.11
Total amount (mg) 3.25 3.23 3.38 3.29 0.08
Fine Particle Fraction (<4.7um) 27.65 33.34 34.41 31.80 3.63
Theoretical amount (mg) 3.26 3.27 3.37 3.30 0.06
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Table A14: M e a s u re m e n ts  o f  p a r t ic le  d is tr ib u t io n  o f  la c to s e  in  N G I te s t  f o r  fo rm u la t io n
c o n ta in in g  F o rM ix
Stage number 1 2 3 average SD
Pre-separator 24.81 30.09 29.41 28.10 2.87
1 8.81 8.33 8.41 8.51 0.25
2 6.90 4.78 7.34 6.34 1.37
3 8.62 8.42 7.78 8.27 0.44
4 11.16 11.79 10.95 11.30 0.43
5 13.32 12.83 14.08 13.41 0.63
6 11.59 10.99 10.97 11.18 0.35
7 8.45 7.38 6.90 7.58 0.79
8 6.30 5.39 4.23 5.30 1.04
Total amount (mg) 2.66 2.83 2.90 2.80 0.12
Fine Particle Fraction (<4.7 urn) 66.33 61.57 62.25 63.38 2.57
Theoretical amount (mg) 3.12 3.09 3.26 3.16 0.09
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In chapter 6, lactose w as added to improve the formulation characteristics o f  ForM ix, and 
different lactose was compared. The dose uniformity results were listed by Table A 15 and A 16.
Table A15: Measurements of dose uniformity for new DPIs, using formulation containing
ForMix and fine lactose.
Dose
Nmuber Blister 1 Blister 2 Blister 3 Blister 4 Blister 5 Blister 6 SD
1 1.05 1.03 0.93 1.05 1.01 0.81 0.09
2 1.04 1.03 0.99 1.06 1.03 0.91 0.05
3 1.05 1.08 1.13 1.03 1.06 1.03 0.04
4 1.07 1.04 0.88 1.03 1.02 0.96 0.07
5 1.07 0.88 0.95 0.94 1.04 1.05 0.08
6 0.99 0.95 0.97 0.94 0.92 0.97 0.03
7 1.03 0.85 0.96 0.96 0.89 1.04 0.08
8 1.06 0.97 1.05 0.94 0.8 1.04 0.10
9 1.05 0.99 0.97 0.98 0.94 1.02 0.04
10 0.97 1.01 1.08 0.93 0.89 0.98 0.07
11 1.17 1.1 1.02 0.86 1.04 0.93 0.11
12 1.11 0.94 1.03 0.91 0.91 0.9 0.09
13 1.04 1.11 1.12 1.1 0.99 0.88 0.09
14 0.97 1.03 0.96 1.07 0.99 0.87 0.07
15 0.92 1.04 1.13 1.15 0.99 0.73 0.16
16 1.01 1.14 1.12 0.86 0.91 0.89 0.12
Average
Dose 1.04 1.01 1.02 0.99 0.96 0.94
SD 0.06 0.08 0.08 0.08 0.07 0.09
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ForMix and large lactose.
Table A16: M e a s u re m e n ts  o f  d o s e  u n ifo rm ity  f o r  n e w  D P Is ,  u s in g  fo rm u la t io n  c o n ta in in g
Dose
Nmuber Blister 1 Blister 2 Blister 3 Blister 4 Blister 5 Blister 6 SD
1 1.31 1.4 1.49 1.4 1.5 1.51 0.08
2 1.32 1.31 1.47 1.42 1.41 1.44 0.07
3 1.41 1.4 1.41 1.47 1.45 1.47 0.03
4 1.26 1.33 1.46 1.39 1.39 1.46 0.08
5 1.34 1.46 1.36 1.42 1.41 1.5 0.06
6 1.35 1.33 1.37 1.38 1.36 1.45 0.04
7 1.33 1.32 1.38 1.38 1.42 1.5 0.07
8 1.37 1.43 1.5 1.53 1.51 1.46 0.06
9 1.39 1.42 1.35 1.52 1.41 1.51 0.07
10 1.36 1.36 1.4 1.4 1.44 1.42 0.03
11 1.49 1.44 1.35 1.54 1.36 1.37 0.08
12 1.42 1.41 1.29 1.47 1.41 1.47 0.07
13 1.38 1.39 1.44 1.49 1.53 1.46 0.06
14 1.46 1.39 1.41 1.44 1.35 1.42 0.04
15 1.44 1.41 1.37 1.34 1.44 1.44 0.04
16 1.35 1.35 1.44 1.44 1.46 1.55 0.08
Average
Dose 1.37 1.38 1.41 1.44 1.43 1.46
SD 0.06 0.05 0.06 0.06 0.05 0.04
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In this research, a filling m achine w as designed to apply for the new  DPIs. The dose uniformity 
for form ulation containing H N A  and large lactose were listed by Table A 17. A lso, Table 18 
indicated the dose uniformity test results for formulation com posed o f  FroM ix and larger lactose. 
Form ulations with fine lactose added as carrier could not be filled  by the filling machine 
successfu lly .
Table A17: Measurements of dose uniformity for filling machine, using formulation
containing HNA and large lactose.
Dose
Nmuber Blister 1 Blister 2 Blister 3 Blister 4 Blister 5 Blister 6 SD
1 0.91 0.65 0.65 0.56 0.56 0.55 0.14
2 0.91 0.63 0.69 0.65 0.72 0.73 0.10
3 0.91 0.62 0.76 0.65 0.79 0.74 0.10
4 0.91 0.70 0.71 0.65 0.87 0.61 0.12
5 0.91 0.62 0.76 0.71 0.63 0.63 0.11
6 0.91 0.65 0.76 0.72 0.63 0.70 0.10
7 0.91 0.69 0.64 0.74 0.66 0.61 0.11
8 0.90 0.64 0.62 0.78 0.62 0.61 0.12
9 0.90 0.67 0.75 0.70 0.71 0.70 0.08
10 0.90 0.63 0.75 0.71 0.62 0.65 0.11
11 0.90 0.70 0.63 0.69 0.75 0.70 0.09
12 0.90 0.73 0.68 0.70 0.69 0.65 0.09
13 0.90 0.71 0.65 0.75 0.66 0.65 0.10
14 0.89 0.67 0.67 0.59 0.71 0.73 0.10
15 0.89 0.69 0.63 0.64 0.75 0.65 0.10
16 0.60 0.66 0.75 0.62 0.68 0.69 0.05
Average
Dose 0.88 0.67 0.69 0.68 0.69 0.66
SD 0.08 0.03 0.05 0.06 0.08 0.05
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Table A18: Measurements of dose uniformity for filling machine, using formulation 
containing ForMix and large lactose made by coffee grinder.
Dose
Nmuber Blister 1 Blister 2 Blister 3 Blister 4 Blister 5 Blister 6 SD
1 1.75 1.81 1.80 1.87 1.79 1.71 0.05
2 1.75 1.85 1.81 1.89 1.92 1.83 0.06
3 1.78 1.76 1.79 1.79 1.81 1.85 0.03
4 1.81 1.94 1.91 1.88 1.96 1.97 0.06
5 1.82 1.78 1.85 1.96 1.84 1.92 0.07
6 1.80 1.86 1.85 1.98 1.90 1.95 0.07
7 1.80 1.74 1.82 1.82 1.91 1.89 0.06
8 1.75 1.74 1.78 1.81 1.84 1.79 0.04
9 1.74 1.74 1.80 1.91 1.79 1.91 0.08
10 1.79 1.74 1.86 1.87 1.89 1.86 0.06
11 1.73 1.86 1.79 1.86 1.88 1.94 0.07
12 1.78 1.77 1.73 1.92 1.87 1.93 0.08
13 1.71 1.73 1.72 1.83 1.76 1.79 0.05
14 1.74 1.68 1.81 1.78 1.79 1.80 0.05
15 1.84 1.73 1.62 1.81 1.91 1.79 0.10
16 1.78 1.77 1.83 1.81 1.85 1.80 0.03
Average
Dose 1.77 1.78 1.80 1.86 1.86 1.86
SD 0.04 0.07 0.07 0.06 0.06 0.07
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The effect o f  preparation o f  drug formulations w as investigated in this research. Formulation 
containing ForM ix and large lactose w as made by coffee grinder and rotary blender respectively. 
A nd both formulations were used for dose uniformity test. The results were listed in Table A 19.
Table A19: Measurements of dose uniformity for filling machine, using formulation 
containing ForMix and large lactose made by rotary blender.
Dose
Nmuber Blister 1 Blister 2 Blister 3 Blister 4 Blister 5 Blister 6 SD
1 1.71 1.80 1.80 1.82 1.78 1.76 0.04
2 1.73 1.74 1.74 1.71 1.73 1.79 0.03
3 1.81 1.75 1.76 1.74 1.78 1.80 0.03
4 1.79 1.70 1.81 1.80 1.82 1.81 0.04
5 1.74 1.73 1.78 1.78 1.70 1.73 0.03
6 1.73 1.79 1.74 1.63 1.63 1.59 0.08
7 1.68 1.66 1.60 1.54 1.59 1.50 0.07
8 1.70 1.52 1.54 1.56 1.41 1.49 0.10
9 1.71 1.64 1.61 1.63 1.58 1.59 0.05
10 1.73 1.74 1.64 1.68 1.63 1.65 0.05
11 1.77 1.81 1.70 1.66 1.54 1.62 0.10
12 1.76 1.65 1.66 1.82 1.69 1.72 0.06
13 1.66 1.61 1.66 1.62 1.71 1.73 0.05
14 1.74 1.76 1.76 1.81 1.76 1.73 0.03
15 1.95 1.87 1.85 1.85 1.84 1.85 0.04
16 1.83 1.85 1.77 1.81 1.80 1.87 0.04
Average
Dose 1.75 1.73 1.71 1.72 1.69 1.70
SD 0.07 0.09 0.09 0.10 0.12 0.12
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In chapter 6, D CU test w as applied for the further research on new  DPIs. The effect o f  puncture 
diameter, preparation m ethod, air resistance, and amount o f  carrier, as w ell as stability test were 
described b y  Table A 20  and A 2 1.
Table A20: Measurement of DCU tests with formulation containing ForMix and larger
lactose













trial 35.59 45.12 21.71 15.60 20.64 21.95 79.36 22.87
2nd
trial 31.75 11.86 18.39 13.37 19.60 9.39 80.40 11.07
Made by rotary 
blender 45.23 13.37 17.29 19.52 16.23 21.28 83.77 3.89
Low resistance 40.52 17.75 24.82 18.38 20.36 29.33 79.64 55.72
High
resistance 45.23 13.37 17.29 19.52 16.23 21.28 83.77 3.89
Table A21: Measurement of DCU tests with formulation containing HNA and larger
lactose









0 day's stability 61.06 10.23 12.38 19.44 6.82 21.74 93.18 9.49
7 days' stability 60.06 34.34 9.41 10.02 12.48 63.85 87.52 16.71
Ratio of HNA 
and lactose 1:4 54.42 14.88 10.78 14.24 14.13 36.71 85.87 10.89
Ratio of HNA 
and lactose 1:9 54.97 10.78 17.00 20.72 14.26 60.46 85.74 10.54
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